



REPORT

Independent Auditors' Report on Compliance for Each Major Programs and on Internal Control over Compliance Required by the Uniform Guidance Schedule of Expenditures of Federal Awards Notes to Schedule of Expenditures of Federal Awards Schedule of Findings and Questioned Costs Summary Schedule of Prior Audit Findings	Independent Auditors' Report	1
Consolidated Statements of Revenues, Expenses and Changes in Net Assets Consolidated Statements of Cash Flows Notes to Consolidated Financial Statements SUPPLEMENTARY INFORMATION Schedule of Compensation, Benefits and Other Payments to Agency Head Consolidating Balance Sheet Consolidating Statement of Revenues, Expense and Changes in Net Assets REPORT REQUIRED BY GOVERNMENT AUDITING STANDARDS AND UNIFORM GUIDANCE Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards Independent Auditors' Report on Compliance for Each Major Programs and on Internal Control over Compliance Required by the Uniform Guidance Schedule of Expenditures of Federal Awards Notes to Schedule of Expenditures of Federal Awards Schedule of Findings and Questioned Costs Summary Schedule of Prior Audit Findings	CONSOLIDATED FINANCIAL STATEMENTS	
Consolidated Statements of Cash Flows Notes to Consolidated Financial Statements SUPPLEMENTARY INFORMATION Schedule of Compensation, Benefits and Other Payments to Agency Head Consolidating Balance Sheet Consolidating Statement of Revenues, Expense and Changes in Net Assets REPORT REQUIRED BY GOVERNMENT AUDITING STANDARDS AND UNIFORM GUIDANCE Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards Independent Auditors' Report on Compliance for Each Major Programs and on Internal Control over Compliance Required by the Uniform Guidance Schedule of Expenditures of Federal Awards Notes to Schedule of Expenditures of Federal Awards Schedule of Findings and Questioned Costs Summary Schedule of Prior Audit Findings	Consolidated Balance Sheets	4
SUPPLEMENTARY INFORMATION Schedule of Compensation, Benefits and Other Payments to Agency Head Consolidating Balance Sheet Consolidating Statement of Revenues, Expense and Changes in Net Assets REPORT REQUIRED BY GOVERNMENT AUDITING STANDARDS AND UNIFORM GUIDANCE Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards Independent Auditors' Report on Compliance for Each Major Programs and on Internal Control over Compliance Required by the Uniform Guidance Schedule of Expenditures of Federal Awards Notes to Schedule of Expenditures of Federal Awards Schedule of Findings and Questioned Costs Summary Schedule of Prior Audit Findings	Consolidated Statements of Revenues, Expenses and Changes in Net Assets	5
Schedule of Compensation, Benefits and Other Payments to Agency Head Consolidating Balance Sheet Consolidating Statement of Revenues, Expense and Changes in Net Assets REPORT REQUIRED BY GOVERNMENT AUDITING STANDARDS AND UNIFORM GUIDANCE Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards Independent Auditors' Report on Compliance for Each Major Programs and on Internal Control over Compliance Required by the Uniform Guidance Schedule of Expenditures of Federal Awards Notes to Schedule of Expenditures of Federal Awards Schedule of Findings and Questioned Costs Summary Schedule of Prior Audit Findings	Consolidated Statements of Cash Flows	7
Schedule of Compensation, Benefits and Other Payments to Agency Head Consolidating Balance Sheet Consolidating Statement of Revenues, Expense and Changes in Net Assets REPORT REQUIRED BY GOVERNMENT AUDITING STANDARDS AND UNIFORM GUIDANCE Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards Independent Auditors' Report on Compliance for Each Major Programs and on Internal Control over Compliance Required by the Uniform Guidance Schedule of Expenditures of Federal Awards Notes to Schedule of Expenditures of Federal Awards Schedule of Findings and Questioned Costs Summary Schedule of Prior Audit Findings	Notes to Consolidated Financial Statements	8
Consolidating Balance Sheet Consolidating Statement of Revenues, Expense and Changes in Net Assets REPORT REQUIRED BY GOVERNMENT AUDITING STANDARDS AND UNIFORM GUIDANCE Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards Independent Auditors' Report on Compliance for Each Major Programs and on Internal Control over Compliance Required by the Uniform Guidance Schedule of Expenditures of Federal Awards Notes to Schedule of Expenditures of Federal Awards Schedule of Findings and Questioned Costs Summary Schedule of Prior Audit Findings	SUPPLEMENTARY INFORMATION	
Consolidating Statement of Revenues, Expense and Changes in Net Assets REPORT REQUIRED BY GOVERNMENT AUDITING STANDARDS AND UNIFORM GUIDANCE Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards Independent Auditors' Report on Compliance for Each Major Programs and on Internal Control over Compliance Required by the Uniform Guidance Schedule of Expenditures of Federal Awards Notes to Schedule of Expenditures of Federal Awards Schedule of Findings and Questioned Costs Summary Schedule of Prior Audit Findings	Schedule of Compensation, Benefits and Other Payments to Agency Head	35
REPORT REQUIRED BY GOVERNMENT AUDITING STANDARDS AND UNIFORM GUIDANCE Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards Independent Auditors' Report on Compliance for Each Major Programs and on Internal Control over Compliance Required by the Uniform Guidance Schedule of Expenditures of Federal Awards Notes to Schedule of Expenditures of Federal Awards Schedule of Findings and Questioned Costs Summary Schedule of Prior Audit Findings	Consolidating Balance Sheet	36
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i> Independent Auditors' Report on Compliance for Each Major Programs and on Internal Control over Compliance Required by the Uniform Guidance Schedule of Expenditures of Federal Awards Notes to Schedule of Expenditures of Federal Awards Schedule of Findings and Questioned Costs Summary Schedule of Prior Audit Findings	Consolidating Statement of Revenues, Expense and Changes in Net Assets	37
Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i> Independent Auditors' Report on Compliance for Each Major Programs and on Internal Control over Compliance Required by the Uniform Guidance Schedule of Expenditures of Federal Awards Notes to Schedule of Expenditures of Federal Awards Schedule of Findings and Questioned Costs Summary Schedule of Prior Audit Findings	REPORT REQUIRED BY GOVERNMENT AUDITING STANDARDS AND UNIFORM GUIDANCE	
Control over Compliance Required by the Uniform Guidance Schedule of Expenditures of Federal Awards Notes to Schedule of Expenditures of Federal Awards Schedule of Findings and Questioned Costs Summary Schedule of Prior Audit Findings	Compliance and Other Matters Based on an Audit of Financial Statements Performed	38
Notes to Schedule of Expenditures of Federal Awards Schedule of Findings and Questioned Costs Summary Schedule of Prior Audit Findings	· · · · · · · · · · · · · · · · · · ·	40
Schedule of Findings and Questioned Costs Summary Schedule of Prior Audit Findings	Schedule of Expenditures of Federal Awards	43
Summary Schedule of Prior Audit Findings	Notes to Schedule of Expenditures of Federal Awards	44
	Schedule of Findings and Questioned Costs	46
Management's Corrective Action Plan	Summary Schedule of Prior Audit Findings	47
	Management's Corrective Action Plan	49



REPORT



Carr, Riggs & Ingram, LLC 111 Veterans Blvd. Suite 350 Metairie, Louisiana 70005

> (504) 837-9116 (504) 837-0123(fax) www.CRIcpa.com

INDEPENDENT AUDITORS' REPORT

To the Board of Directors CommCare Corporation Mandeville, Louisiana

Opinion

We have audited the accompanying consolidated financial statements of CommCare Corporation (the Company), which comprise the consolidated balance sheets as of June 30, 2023 and 2022, and the related consolidated statements of revenues, expenses and changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of CommCare Corporation as of June 30, 2023 and 2022, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibility of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the

Company's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditors' Responsibility for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of expressing
 an opinion on the effectiveness of the Company's internal control. Accordingly, no such
 opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying Schedule of Compensation, Benefits and Other Payments to Agency Head, Consolidating Balance Sheet, and Consolidating Statement of Revenues, Expenses and Changes in Net Assets as of and for the year ended June 30, 2023, and schedule of expenditures of federal awards, as required by Title 2 U.S. Code of Federal Regulations (CFR) Part 200 Uniform Administrative Requirements, and Cost Principles and Audit Requirements for Federal Awards are presented for purposes of additional analysis and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, except for the matter described below, the information is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

The accompanying Consolidating Balance Sheet and Consolidating Statement of Revenues, Expenses and Changes in Net Assets for the year ended June 30, 2023 does not include right-of-use lease assets and lease liabilities for material related-party leases that fully eliminate upon consolidation. Management has informed us that they have not determined the effects of not including related-party leases in the consolidating information.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated March 12, 2024 on our consideration of the Company's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Company's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards in considering the Company's internal control over financial reporting and compliance.

Metairie, Louisiana March 12, 2024

Carr, Riggs & Ungram, L.L.C.



FINANCIAL STATEMENTS

CommCare Corporation Consolidated Balance Sheets

June 30,		2023		202
Assets				
Current assets				
Cash and cash equivalents	\$	15,724,121	\$	22,061,881
Restricted cash	•	560,000	•	560,000
Accounts receivable, net		20,995,420		17,504,105
Prepaid expenses and other current assets		4,063,099		1,846,904
Total current assets		41,342,640		41,972,89
Non-current assets				
Restricted cash		6,919,287		4,412,539
Notes receivable		17,285,725		17,285,72
Intangible assets		51,541,833		18,871,51
Goodwill		6,456,944		6,456,94
Fair value of interest rate swaps		3,358,957		1,186,82
Miscellaneous		85,208		582,26
Operating lease right-of-use assets, net		5,424,783		-
Property and equipment, net		229,930,671		157,456,22
Total non-current assets		321,003,408		206,252,02
Total Assets	\$	362,346,048	\$	248,224,91
Total Assets Liabilities and Net Assets Current liabilities	\$	362,346,048	\$	248,224,91
Liabilities and Net Assets	\$	362,346,048 18,341,901	\$	
Liabilities and Net Assets Current liabilities				18,866,71
Liabilities and Net Assets Current liabilities Accounts payable and accrued expenses Current portion of long-term debt Current portion of operating leases		18,341,901		18,866,71
Liabilities and Net Assets Current liabilities Accounts payable and accrued expenses Current portion of long-term debt		18,341,901 7,012,805		18,866,71 2,304,06: -
Liabilities and Net Assets Current liabilities Accounts payable and accrued expenses Current portion of long-term debt Current portion of operating leases		18,341,901 7,012,805 992,660		18,866,71 2,304,06 -
Liabilities and Net Assets Current liabilities Accounts payable and accrued expenses Current portion of long-term debt Current portion of operating leases Total current liabilities		18,341,901 7,012,805 992,660		18,866,71 2,304,06: -
Liabilities and Net Assets Current liabilities Accounts payable and accrued expenses Current portion of long-term debt Current portion of operating leases Total current liabilities Long-term liabilities		18,341,901 7,012,805 992,660		18,866,71 2,304,06 - 21,170,77
Liabilities and Net Assets Current liabilities Accounts payable and accrued expenses Current portion of long-term debt Current portion of operating leases Total current liabilities Long-term liabilities Long-term debt, less current portion and less unamortized debt issuance costs Operating Lease liabilities, less current portion		18,341,901 7,012,805 992,660 26,347,366		18,866,71: 2,304,06: - 21,170,77
Liabilities and Net Assets Current liabilities Accounts payable and accrued expenses Current portion of long-term debt Current portion of operating leases Total current liabilities Long-term liabilities Long-term debt, less current portion and less unamortized debt issuance costs		18,341,901 7,012,805 992,660 26,347,366		18,866,71 2,304,06 - 21,170,77 134,780,33
Liabilities and Net Assets Current liabilities Accounts payable and accrued expenses Current portion of long-term debt Current portion of operating leases Total current liabilities Long-term liabilities Long-term debt, less current portion and less unamortized debt issuance costs Operating Lease liabilities, less current portion		18,341,901 7,012,805 992,660 26,347,366 222,078,863 4,441,851		18,866,71 2,304,06 - 21,170,77 134,780,33 - 134,780,33
Liabilities and Net Assets Current liabilities Accounts payable and accrued expenses Current portion of long-term debt Current portion of operating leases Total current liabilities Long-term liabilities Long-term debt, less current portion and less unamortized debt issuance costs Operating Lease liabilities, less current portion Total long-term liabilities		18,341,901 7,012,805 992,660 26,347,366 222,078,863 4,441,851 226,520,714		18,866,71 2,304,06 - 21,170,77 134,780,33 - 134,780,33
Liabilities and Net Assets Current liabilities Accounts payable and accrued expenses Current portion of long-term debt Current portion of operating leases Total current liabilities Long-term liabilities Long-term debt, less current portion and less unamortized debt issuance costs Operating Lease liabilities, less current portion Total long-term liabilities Total liabilities		18,341,901 7,012,805 992,660 26,347,366 222,078,863 4,441,851 226,520,714		18,866,71 2,304,06 - 21,170,77 134,780,33 - 134,780,33 155,951,10
Liabilities and Net Assets Current liabilities Accounts payable and accrued expenses Current portion of long-term debt Current portion of operating leases Total current liabilities Long-term liabilities Long-term debt, less current portion and less unamortized debt issuance costs Operating Lease liabilities, less current portion Total long-term liabilities Total liabilities Net assets without donor restrictions		18,341,901 7,012,805 992,660 26,347,366 222,078,863 4,441,851 226,520,714 252,868,080		18,866,71 2,304,06 - 21,170,77 134,780,33 - 134,780,33 155,951,10
Liabilities and Net Assets Current liabilities Accounts payable and accrued expenses Current portion of long-term debt Current portion of operating leases Total current liabilities Long-term liabilities Long-term debt, less current portion and less unamortized debt issuance costs Operating Lease liabilities, less current portion Total long-term liabilities Total liabilities Net assets without donor restrictions CommCare Corporation		18,341,901 7,012,805 992,660 26,347,366 222,078,863 4,441,851 226,520,714 252,868,080		18,866,71 2,304,06 - 21,170,77

CommCare Corporation Consolidated Statements of Revenues, Expenses, and Changes in Net Assets

For the years ended June 30,	2023	2022
Revenue without donor restrictions, gains, and other support		
Patient service revenue, net \$	146,220,104 \$	121,926,235
Pharmacy sales	13,238,142	11,524,103
Premium income	6,609,277	5,113,943
Management fee income	790,337	612,591
Lease income	174,121	715,245
Contribution revenue	· -	1,594,732
Grant revenue	10,407,387	2,182,141
Other operating revenues	947,978	480,520
Total revenue without donor restrictions, gains, and other support	178,387,346	144,149,510
Operating Expenses		
Nursing services	66,334,552	50,526,401
General and administrative	40,560,198	36,204,424
Therapy and ancillary services	10,148,412	9,370,327
Cost of pharmacy sales	10,900,367	9,133,898
Dietary and food	8,873,628	7,332,797
Depreciation and amortization	8,318,560	7,332,179
Plant operations and maintenance	7,171,134	6,213,411
Provider fees	6,032,005	5,501,424
Housekeeping and laundry	4,545,185	3,648,496
Activities and social services	2,163,899	1,816,906
Provision for bad debts	1,265,953	1,667,229
Lease expense	1,324,207	843,430
Advertising and marketing costs	1,162,475	1,109,821
Community services	57,269	79,036
Total operating expenses	168,857,844	140,779,779
Operating income	9,529,502	3,369,731
Non-operating revenues (expenses)	(4.57.222)	44 200 744
(Loss) gain on disposal of assets	(167,328)	11,288,741
Miscellaneous (expense) income	(377,756)	978,190
Gain (loss) on equity method investment	-	(585,198)
Interest income	432,956	456,753
Interest expense	(7,571,820)	(3,718,129)
Unrealized gain (loss) on swap	2,172,132	1,443,074
Gain on acquisition	9,412,611	<u>-</u>
Total non-operating revenues (expenses)	3,900,795	9,863,431
Changes in net assets without donor restrictions	13,430,297	13,233,162
Less change in net assets attributable to noncontrolling interests	(1,293,210)	(1,357,557)
Change in net assets attributable to CommCare Corporation	12,137,087	11,875,605
	(continued)	(continued)

CommCare Corporation Consolidated Statements of Revenues, Expenses, and Changes in Net Assets

For the years ended June 30,	2023	2022
Net assets		
Beginning of year	92,273,812	80,435,650
Distributions to noncontrolling shareholder in subsidiary	(1,203,384)	(1,395,000)
Contributions from noncontrolling shareholder in subsidiary	4,977,243	-
End of year	\$ 109,477,968 \$	92,273,812
	(concluded)	(concluded)

Commcare Corporation Consolidated Statements of Cash Flows

For the Years Ended June 30,		2023		2022
Operating Activities				
Change in net assets	\$	13,430,297	\$	13,233,162
Adjustments to reconcile change in net assets to				
net cash provided by operating activities:				
Loss (gain) on disposal of assets		167,328		(11,288,741)
Loss on equity method investment		-		585,198
Depreciation and amortization		8,882,469		7,494,840
Amortization of right-of-use assets		791,426		-
Provision for bad debts		1,265,953		1,667,229
Gain on acquisition		(9,412,611)		-
Changes in assets and liabilities:				
Receivables		(4,757,268)		(1,562,058)
Prepaid expenses and miscellaneous		(1,668,232)		(476,099)
Accounts payable and accrued expenses		1,330,849		1,561,752
Fair value of interest rate swap		(2,172,132)		(1,443,074)
Operating lease liabilities		(781,698)		-
Changes in assets held for sale (discontinued operations)		-		18,440
Changes in liabilities held for sale (discontinued operations)		-		(2,122,812)
Net cash provided by operating activities		7,076,381		7,667,837
Investing Activities				
Purchases of property and equipment		(13,319,037)		(30,038,766)
Acquisition net of cash acquired		(17,852,274)		-
Purchase of other assets		(11,060,539)		(4,500,000)
Proceeds from disposal of assets and equity method investment		-		24,948,415
Net cash used in investing activities		(42,231,850)		(9,590,351)
Financing Activities				
Payments on notes payable		(3,157,269)		(106,307,960)
Issuance of notes payable		31,036,643		94,832,232
Debt issuance costs		(328,776)		(834,493)
Distributions to non controlling shareholder in subsidiary		(1,203,384)		(2,606,659)
Contributions from non controlling shareholder in subsidiary		4,977,243		-
Net cash provided by (used in) financing activities		31,324,457		(14,916,880)
Net change in cash, cash equivalents, and restricted cash		(3,831,012)		(16,839,394)
Net change in easi, easi equivalents, and restricted easi		(3,031,012)		(10,033,334)
Net cash, cash equivalents, and restricted cash at beginning of year		27,034,420		43,873,814
Net cash, cash equivalents, and restricted cash at end of year	\$	23,203,408	\$	27,034,420
SUPPLEMENTAL DISCLOSURE OF CASH PAID FOR INTEREST				
Cash payments for interest	\$	7,958,253	\$	4,064,960
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING	ACTIVITIES			
Debt assumed in acquisition	\$	63,357,597	\$	_
Note issued to seller in acquisition	Ś	550,000	\$	
Capital expenditures in accounts payable	\$	25,061	\$	1,880,724
Lease liabilities arising from obtaining right-of-use assets	\$	6,216,209	\$	-
RECONCILIATION OF CASH, CASH EQUIVALENTS, AND RESTRICTED CASH		·		
		45 55 454	•	22 224 2
Cash and cash equivalents	\$	15,724,121	\$	22,061,881
Restricted cash		7,479,287		4,972,539
Total cash, cash equivalents, and restricted cash	\$	23,203,408	\$	27,034,420
• •		· · ·	•	

Note 1: DESCRIPTION OF THE ORGANIZATION

Organization and Business Description

CommCare Corporation is a non-profit entity that owns and operates skilled nursing, assisted living and independent living facilities. The facilities include 2,488 extended-care beds that are licensed and permitted for current operation by the Louisiana Department of Health and Hospitals and other state or Federal regulatory agencies having jurisdiction over the operations of the facilities. The Company also manages 142 licensed beds for third parties. CommCare Corporation also owns a 55% share of a pharmacy, 55% share of a hospice and home health company, 100% of nine asset holding companies, 100% of a management company, and 100% of an insurance provider that are all located in Louisiana, with the exception of the hospice and home health company that also has operations in Mississippi. See Note 17 for acquisitions during June 30, 2023.

Note 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of CommCare Corporation and its wholly owned subsidiaries (collectively the "Company"), CommCare Management Corporation, Dignity Care Corporation, CommCare Louisiana (a non-profit corporation) and its majority owned subsidiaries CCC Pharmacy, LLC and Post Acute Holdings, LLC. The Company also wholly owns the following real estate holding companies whose primary purpose is to own and lease skilled nursing facilities with the Company: CommCare Avoyelles (a non-profit corporation), Commcare Tangipahoa (a non-profit corporation), CommCare Natchitoches (a non-profit corporation), CommCare Center Point (a non-profit corporation), CommCare Ouachita (a non-profit corporation), Chateau De Notre Dame Facilities Corporation (a non-profit corporation), and Our Lady of Wisdom Facility Corporation (a non-profit corporation). Significant intercompany transactions and balances have been eliminated through consolidation.

Basis of Accounting

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The Financial Accounting Standards Board (FASB) provides authoritative guidance regarding U.S. GAAP through the Accounting Standards Codification (ASC) and related Accounting Standards Updates (ASUs).

Use of Estimates

The preparation of U.S. GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Estimates that are particularly susceptible to significant change in the near term include an allowance for uncollectible accounts and claims incurred but not reported.

Cash and Cash Equivalents

Cash and cash equivalents include cash and all highly liquid investments with an original maturity date of 90 days or less. Restricted cash is required by the loan agreements in relation to the construction of facilities, by regulatory requirements, and requirements in relation to a letter of credit from a financial institution. Cash was restricted for the following at June 30, 2023 and 2022:

Restricted at June 30,	2023	2022
Debt payments	\$ 4,479,287	\$ 1,972,539
Regulatory Requirement	3,000,000	3,000,000
Total	\$ 7,479,287	\$ 4,972,539

Accounts Receivable

The Company grants credit without collateral to its patients and other customers, most of whom are local residents and are covered under third-party payor agreements. Management performs an evaluation of amounts due from third-party payors (including estimated cost report settlements), residents, responsible parties, and insurers, and reduces accounts receivable by an allowance for uncollectible accounts. The allowance is calculated based on a number of factors including the age of the accounts, the payor type, and any ongoing disputes with third-party payors. The allowance for uncollectible accounts was \$1,149,608 and \$2,201,639 as of June 30, 2023 and 2022, respectively. Substantially all accounts receivable are pledged to secure debt (see Note 8).

Property and Equipment

Property and equipment are recorded at cost. Renewals and improvements that extend the economic life of such assets are capitalized. Expenditures for maintenance, repairs and other renewals are expensed. Upon disposition of a capital asset, the asset's cost and accumulated depreciation are removed from the balance sheet and any gain or loss is included in the statements of revenues, expenses and changes in net assets. Depreciation is recorded over the estimated useful life of an asset using the straight-line method.

Property and Equipment (Continued)

The Company records impairment losses on long-lived assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. No impairment loss was recorded by the Company for the years ended June 30, 2023 and 2022, respectively.

The useful life of property and equipment was as follows at June 30:

	Depreciable Life
Land	Not depreciated
Land improvements	5-15 years
Buildings and improvements	10-39 years
Furniture, fixtures and equipment	3-5 years
Construction in progress	Not depreciated

Leases

The Company leases office space, land, and equipment. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities on the consolidated balance sheets.

ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, the Company uses a risk-free rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

The lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Goodwill

In accordance with authoritative guidance on intangible assets, goodwill is tested for impairment annually as of June 30 or on an interim basis if events or circumstances indicate that the fair value of the asset has decreased below its carrying value. The Company performed a qualitative assessment of events and circumstances to determine whether it was more likely than not that the fair value of the reporting unit that contained the goodwill was less than its carrying amount. Based on this assessment it was determined that it was not more likely than not that the fair value of the reporting unit was less than its carrying amount. As a result of this assessment, no impairment loss was recognized during the years ended June 30, 2023 and 2022.

Intangible Assets

Intangible assets consist primarily of Certificates of Need (CON) acquired through the purchase of existing nursing homes or through direct purchase of existing licenses. Louisiana statutes require that nursing home operators obtain a CON prior to the addition or construction of new nursing home beds, the addition of new services or certain capital expenditures in excess of defined levels. A CON certifies that the state has made a determination that a need exists for such new or additional beds, new services or capital expenditures. The CONs have an indefinite useful life. Management evaluates the net carrying value of all intangible assets for impairment when circumstances indicate that the assets might be impaired, but not less than annually.

As a result of this assessment, no impairment loss was recognized during the years ended June 30, 2023 and 2022. In addition to the CONs, intangible assets also include costs related to obtaining new market tax credits utilized in the financing of an existing facility. Total unamortized tax credit costs were \$28,947 and \$39,163 as of June 30, 2023 and 2022, respectively. Total amortization expense related to new market tax credits was \$10,216 and \$10,217 for the years ended June 30, 2023 and 2022, respectively.

Deferred Financing Costs, Net

Deferred financing costs are amortized over the term of the debt instrument using the straight-line method. Accounting principles generally accepted in the United States of America require that the effective interest method be used to amortize financing costs; however, management believes the effect of using the straight-line method is not materially different from the results that would have been obtained under the effective interest method.

Interest expense related to deferred financing costs was \$563,909 and \$167,345 for the years ended June 30, 2023 and 2022, respectively.

Interest Rate Swaps

The Company has five interest rate swap agreements to convert the variable interest on certain loans to fixed rates. Based on changes in interest rates subsequent to entering into the agreement, the fair value of the swaps were \$3,358,957 and \$1,186,825 at June 30, 2023 and 2022, respectively. The fair value of the swaps is considered to be a Level 2 fair value measurement. The change in the asset or liability is reported as a component of non-operating revenues (expenses) on the consolidated statements of revenues, expenses, and changes in net assets.

Compensated Absences

Employees accumulate paid time off (PTO) at varying rates according to years of service. Employees become vested in PTO upon completion of ninety days of employment. Upon termination, all unused PTO hours are paid to the employee at the employee's current rate of pay provided that the employee has successfully completed ninety days of employment. Accrued PTO cannot exceed the maximum amount of PTO that can be earned in one year's time. Accrued PTO was \$1,314,609 and \$1,049,137 as of June 30, 2023 and 2022, respectively. Accrued PTO is included in accounts payable and accrued expenses on the consolidated balance sheets.

Claims Payable and Reserves for Incurred but Unreported Claims

The Company provides reserves for estimated incurred but unreported physician, hospital, other professional, and pharmacy services rendered to enrolled members of the insurance subsidiary (Dignity Care). This reserve is reported net of anticipated reinsurance recoveries. The reserve is estimated by the use of completion factors applied to historical lag patterns and projection of permember-per-month cost trends. Medical cost adjustments to prior period estimates are reflected in the current period and changes in these estimates could be significant. While the ultimate amount of claims and losses are dependent upon future developments, management is of the opinion that the recorded reserves are adequate to cover such costs.

Premium Deficiency Reserve

The Company assesses the profitability of its Dignity Care insurance contracts when current operating results or forecasts indicate probable future losses for a line of business. The Company records a premium deficiency liability in current operations to the extent that the sum of expected future medical costs, claim adjustment expenses, and administration costs exceed the premiums to be collected for the remainder of a contract period. Investment income is not considered in the calculation of the premium deficiency liability.

Net Assets

The Company reports information regarding its financial position and activities according to two classes of net assets that are based upon the existence or absence of restrictions on use that are placed by its donors: net assets without donor restrictions and net assets with donor restrictions.

Net assets without donor restrictions are resources available to support operations and not subject to donor restrictions. The only limits on the use of net assets without donor restrictions are the broad limits resulting from the nature of the Company, the environment in which it operates, the purposes specified in it corporate documents and its application for tax-exempt status, and any limits resulting from contractual agreements with creditors and others that are entered into in the course of its operations.

Net Assets (Continued)

Net assets with donor restrictions are resources that are subject to donor-imposed restrictions. Some restrictions are temporary in nature, such as those that are restricted by a donor for use for a particular purpose or in a particular future period. Other restrictions may be perpetual in nature; such as those that are restricted by a donor that the resources be maintained in perpetuity.

When a donor's restriction is satisfied, either by using the resources in the manner specified by the donor or by the passage of time, the expiration of the restriction is reported in the consolidated financial statements by reclassifying the net assets from net assets with donor restrictions to net assets without donor restrictions. At June 30, 2023 and 2022 there were no net assets with donor restrictions.

Noncontrolling Interest in Subsidiaries

The Company has ownership interests in subsidiaries that are less than 100% but are controlled by the Company and therefore consolidated. During the years ended June 30, 2023 and 2022 the Company distributed \$1,203,384 and \$1,395,000 to the noncontrolling shareholders of CCC Pharmacy, LLC. The Company received \$4,977,243 in contributions from the noncontrolling shareholders of Post Acute Holdings, LLC during the year ended June 30, 2023.

Fair Value Measurements

Accounting Standards Codification (ASC) 820-10 establishes a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

- Level 1—Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
- Level 2—Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial statements.
- Level 3—Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Company's financial instruments consist of cash, accounts receivable, accounts payable, and interest rate swaps. The recorded values of cash, accounts receivable, and accounts payable, approximate fair value based on their short-term nature.

Note 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Fair Value Measurements (Continued)

The recorded values of interest rate swaps are measured on a recurring basis primarily utilizing Level 2 inputs including forecasted interest rates and quoted prices for similar instruments in active markets.

Patient Service Revenue and Concentration of Credit Risk

Effective July 1, 2020, the Company adopted ASC 606 using the modified retrospective method. Patient service revenue and receivables are reported at the amount that reflects the consideration the Company expects to be entitled for providing patient care. These amounts are due from patients, third-party payors (including managed care payors and government programs), and others, and include variable consideration for retroactive revenue adjustments due to settlement of reviews and audits. Generally, the Company bills the patients and third-party payors after the services are performed. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges. The Company believes that this method provides a reasonable depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. The Company measures the performance obligation from admission into the facility to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. These services are considered to be a single performance obligation. Revenue for performance obligations satisfied at a point in time is recognized when services are provided. Management believes this method provides a faithful depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations.

Because its performance obligations relate to contracts with a duration of less than one year, the Company has elected to apply the optional exemption provided in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606-10-60-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

As provided for under the guidance, the Company does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less.

Patient Service Revenue and Concentration of Credit Risk (Continued)

The Company is utilizing the portfolio approach practical expedient in ASC 606 for contracts related to patient service revenue. The Company accounts for the contracts within each portfolio as a collective group, rather than individual contracts, based on the payment pattern expected in each portfolio category and the similar nature and characteristics of the patients within each portfolio. The portfolios consist of major payor classes for services performed. Based on historical collection trends and other analyses, the Company has concluded that revenue for a given portfolio would not be materially different from accounting for revenue on a contract-by-contract basis.

Patient service revenue is recorded at established billing rates or at the amount realizable under agreements with third-party payors for services rendered. Revenues under third-party payor agreements are subject to examination and retroactive adjustment. Provisions for estimated third-party payor settlements are provided in the period the related services are rendered. Differences between the amounts accrued and subsequent settlements are recorded in operations in the year of settlement. The mix of net revenues earned from the delivery of patient services were as follows:

For the year ended June 30,	2023	2022
Medicaid	55%	57%
Medicare	31%	29%
Other, including VA, Hospice and Private Payment	14%	14%
	100%	100%

The mix of net receivables outstanding from the delivery of patient services were as follows:

June 30,	2023	2022
Medicaid	52%	54%
Medicare	24%	28%
Other, including VA, Hospice and Private Payment	24%	18%
	100%	100%

Medicare and Medicaid

Payment for services provided to inpatient acute Medicare program beneficiaries, and certain outpatient services, is based on a combination of prospectively determined rates per discharge and reimbursement for certain capital and medical education costs, as defined. These rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors. Medicare inpatient nonacute service and services rendered to Medicaid program beneficiaries are paid based on a cost reimbursement methodology with certain limitations and rate schedules. The Company is reimbursed for cost reimbursable items at a tentative rate with final settlement determined after submission of annual cost reports by the Company and audits thereof by fiscal intermediaries.

Note 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Medicare and Medicaid (Continued)

Final settlements are estimated and recorded in the financial statements in the year in which they occur. The estimated settlements recorded at June 30, 2023, could differ from actual settlements based on the results of cost report audits. Cost reports for all years before 2022 have been audited and settled as of June 30, 2023.

During 2023 and 2022, there were no changes in patient service revenues in the accompanying statements of operations to reflect changes in the estimated settlements for prior years. Future changes in the Medicare and Medicaid programs and the possible reduction of funding could have an adverse impact on the Company. In the opinion of management, adequate reserves for estimated final settlements have been provided as of June 30, 2023 and 2022, respectively.

Grant Revenue

All of the Company's grant revenues are from disaster grants for presidentially declared disasters related to COVID-19, hurricanes, and winter storms. The benefits received by the Company as a result of the assets transferred are not equivalent to commensurate value received by the government agencies and are therefore not considered exchange transactions. Grant revenue is analyzed for measurable performance-related barriers or other barriers. Revenue is recognized as barriers are met.

Other Programs

The Company has patient service agreements with certain commercial insurance carriers, HMOs, and preferred provider organizations. The basis for payment to the Company under these agreements includes prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company's compliance with these laws and regulations, and it is not possible to determine the impact, if any, such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims.

Other Programs (Continued)

Settlements with third-party payors for retroactive adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor, and the Company's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved.

Estimated settlements are adjusted in future periods as adjustments become known based on newly available information or as years are settled or are no longer subject to such audits, reviews, and investigations.

Other Revenue Recognition

Premium income is based on contracts with Centers for Medicare and Medicaid Services (CMS) to provide medical services to Medicare enrollees in return for a capitated payment. Substantially all of the premiums are received from CMS under Medicare Advantage contracts. Premiums are due monthly and are recognized as income during the period that the Plan is obligated to provide services to its members.

Management fees earned by the management company are recorded when performance obligations are met.

Revenues from pharmacy sales are recorded at the time performance obligations are met.

Lease income is recorded when earned per the terms of the lease agreement.

Advertising Costs

Advertising costs are expensed as incurred. During the years ended June 30, 2023 and 2022, advertising costs totaled \$156,298 and \$156,109, respectively.

Income Taxes

CommCare Management Corporation is a C-corporation for income tax purposes and income tax expense is calculated based on the liability method. During the year ended June 30, 2023 there were no differences between the book basis and the tax basis of CommCare Management Corporation's assets and liabilities, and therefore there were no deferred tax assets or liabilities recorded at June 30, 2023. Income tax expense of \$355,673 and \$0 was recorded in miscellaneous (expense) income on the consolidated statements of revenues, expenses and changes in net assets during the year ended June 30, 2023 and 2022, respectively.

Income Taxes (Continued)

No provision for income taxes has been made in the accompanying consolidated financial statements other than for CommCare Management Corporation. The Internal Revenue Service has determined that CommCare Corporation and its nonprofit subsidiaries qualify as 503(c)(3) organizations and are exempt from income taxes. The Company's for profit subsidiaries, other than CommCare Management Corporation, have elected to be taxed as partnerships and all income flows through to the individual members.

Generally accepted accounting principles require an organization to account for uncertainties in income taxes. The interpretation requires recognition and measurement of uncertain income tax positions using a "more-likely-than-not" approach.

The Company has reviewed its tax positions and determined there were no outstanding or retroactive tax positions with less than a 50% likelihood of being sustained upon examination of taxing authorities.

Interest

The Company capitalizes interest costs on qualifying construction in progress based on an imputed interest rate estimating the average cost of borrowed funds. Such capitalized interest becomes part of the cost of the related asset and is depreciated over its estimated life.

Subsequent Events

Management has evaluated subsequent events through the date that the financial statements were available to be issued, March 12, 2024. See Note 18 for relevant disclosures. No subsequent events occurring after this date have been evaluated for inclusion in these consolidated financial statements.

Recent Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (FASB) issued guidance (Accounting Standards Codification [ASC] 842, Leases) to increase transparency and comparability among organizations by requiring the recognition of right-of-use (ROU) assets and lease liabilities on the balance sheet. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases.

Recent Accounting Pronouncements (Continued)

The Company adopted the standard effective July 1, 2022 and recognized and measured leases existing at, or entered into after, July 1, 2022 (the beginning of the earliest comparative period presented) using a modified retrospective approach, with certain practical expedients available.

The Company elected the available practical expedients to account for existing operating leases as operating leases, respectively, under the new guidance, without reassessing (a) whether the contracts contain leases under the new standard, (b) whether classification of operating leases would be different in accordance with the new guidance, or (c) whether the unamortized initial direct costs before transition adjustments would have met the definition of initial direct costs in the new guidance at lease commencement.

As a result of the adoption of the new lease accounting guidance, the Company recognized on July 1, 2022 a lease liability of \$5,637,886, which represents the present value of the remaining operating lease payments, discounted using the risk free, and a right-of-use asset of \$5,637,886.

The standard had a material impact on the Company's consolidated balance sheets, but did not have an impact on the consolidated statements of revenues, expenses, and changes in net assets, nor consolidated statements of cash flows. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

Note 3: FINANCIAL ASSET AVAILABILITY

The Company maintains its financial assets primarily in cash and cash equivalents and accounts receivable to provide liquidity to ensure funds are available as the Company's expenditures come due. The following reflects the Company's financial assets as of the balance sheet date, reduced by amounts not available for general use within one year of the balance sheet date because of contractual or donor-imposed restrictions.

June 30,		2023	2022
Financial assets, at year-end	\$	36,719,541	\$ 39,565,986
Less those not available for general expenditures within one due to contractual or donor-imposed restrictions Restricted by donor with time or purpose restrictions	year,	-	-
Board designations		-	
Financial assets available to meet cash needs for general expenditures within one year	\$	36,719,541	\$ 39,565,986

Note 3: FINANCIAL ASSET AVAILABILITY (Continued)

Financial assets at year-end as noted in the above schedule exclude non-current assets, prepaid expenses, other current assets, and restricted cash.

Note 4: NOTES RECEIVABLE

On July 1, 2017, the Company entered into a new markets tax credit (NMTC) transaction to partially finance the construction of a new skilled nursing facility in Ponchatoula, Louisiana. As part of the NMTC financing, the Company had a note receivable from a financial institution of \$6,166,400 at June 30, 2023 and 2022, respectively. Interest accrues at a fixed rate of 4.95% and is payable quarterly. The final payment of all outstanding principal will be due on the maturity date of the note, July 7, 2024.

On May 26, 2021, the Company entered into a new markets tax credit (NMTC) transaction to partially finance the construction of a new skilled nursing facility in Natchitoches, Louisiana. As part of the NMTC financing, the Company had a note receivable from a financial institution of \$6,597,900 at June 30, 2023 and 2022, respectively. Interest accrues at a fixed rate per annum of 1.00% and is payable quarterly. The final payment of all outstanding principal will be due on the maturity date of the note, May 25, 2051.

On May 26, 2021, the Company entered into a new markets tax credit (NMTC) transaction to partially finance the construction of a new skilled nursing facility in Natchitoches, Louisiana. As part of the NMTC financing, the Company had a note receivable from Twain Investment Fund 489 of \$3,492,900 at June 30, 2023 and 2022, respectively. Interest accrues at a fixed rate per annum of 1.00% and is payable quarterly. The final payment of all outstanding principal will be due on the maturity date of the note, May 25, 2051.

On May 26, 2021, the Company entered into a new markets tax credit (NMTC) transaction to partially finance the construction of a new skilled nursing facility in Natchitoches, Louisiana. As part of the NMTC financing, the Company had a note receivable from Twain Investment Fund 546 of \$1,028,525 at June 30, 2023 and 2022, respectively. Interest accrues at a fixed rate per annum of 1.21% and is payable quarterly. The final payment of all outstanding principal will be due on the maturity date of the note, May 25, 2051.

Note 4: NOTES RECEIVABLE (CONTINUED)

Payments to be received on the notes receivable balances in the subsequent fiscal years are as follows:

June 30,	
2024	\$ -
2025	6,166,400
2026	-
2027	-
2028	-
Thereafter	11,119,325
Total	\$ 17,285,725

Note 5: EQUITY METHOD INVESTMENT

The Company had a fifty percent interest in a skilled nursing home operating company, Minden Community Care Center, LLC, which was formed in 2021. On December 1, 2021 the Company sold its interests in the operating company and the land and building that it was leasing to the operating company for \$16,232,000. As part of the sale the debt associated with the fixed assets was paid off and the Company recognized a gain of \$854,697 which is included in gain on disposal of assets on the consolidated statements of revenues, expenses, and changes in net assets. The Company's pro rata share of net income prior to the sale for the year ended June 30, 2022 was \$22,480.

Note 6: PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at June 30:

	2023	2022
Land	\$ 20,162,070	\$ 14,256,092
Land improvements	4,153,434	3,820,491
Buildings and improvements	231,850,391	134,539,979
Furniture, fixtures and equipment	34,054,332	26,763,626
Construction in progress	1,455,801	32,916,311
Total property and equipment	291,676,028	212,296,499
Less accumulated depreciation	(61,745,357)	(54,840,273)
	\$ 229,930,671	\$ 157,456,226

Note 6: PROPERTY AND EQUIPMENT (CONTINUED)

Depreciation expense was \$8,308,344 and \$7,321,962 for the years ended June 30, 2023 and 2022, respectively. Substantially all land, buildings, improvements, and equipment are pledged to secure debt (see Note 8). For the year ended June 30, 2023 and 2022, \$950,342 and \$492,777 of interest was capitalized and \$75,922 and \$492,777 included in construction in progress, respectively.

Construction in progress at June 30, 2023 primarily consisted of construction on newly acquired facilities in Mandeville and New Orleans, Louisiana and at June 30, 2022 primarily consisted of the construction of facilities in Lake Charles and Natchitoches, Louisiana. As of June 30, 2022 the Company estimates that it will incur an additional \$11,588,257 to complete the construction.

Note 7: ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consisted of the following at June 30:

	2023	2022
Accounts payable	\$ 6,047,463	\$ 8,976,211
Accrued salaries, wages, benefits, and payroll taxes	7,380,684	5,160,587
Accrued professional liability	2,016,211	2,200,000
Other accrued expenses	2,897,543	2,529,917
	\$ 18,341,901	\$ 18,866,715

In response to the COVID-19 pandemic, CMS advanced funds to the Company under the CMS Accelerated and Advance Payment Program. The funds advanced under this program are required to begin being repaid 12 months from the award date. Patient service billings are offset against the advanced funds based on the following schedule. Beginning 12 months after the advance payments were made, CMS will automatically recoup 25% of all payments for 11 months. After the 11 months have elapsed, if there are still amounts yet to be repaid from the advance payment, CMS will automatically recoup 50% of all payments for 6 months. At the end of this six-month period, if there are any amounts still unpaid, CMS will send a letter to the provider requesting the full repayment of the amount still outstanding. Recoupment began in April 2021. Included in other accrued expenses at June 30, 2023 and 2022 is \$0 and \$14,296 of advance payments from CMS.

A liability for premium deficiency losses are recorded in accounts payable and accrued expenses on the consolidated balance sheet. A liability for premium deficiency losses is an actuarial estimate that is recognized when it is probable that expected claim losses and allocable administrative expenses will exceed future premiums on existing health and other contracts. Premium deficiency losses are generally released over the period that the contract is in a loss position. The Company recorded \$600,000 and \$750,000 premium deficiency reserve ("PDR") at June 30, 2023 and 2022, respectively, for its Medicare Advantage market segment. Medicare Advantage contracts are considered short duration insurance contracts.

Note 7: ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Continued)

Included in accounts payable are claims payable that represent the amount of payments to be made on individual claims which have been reported to the Plan, as well as estimates of claims incurred which have not yet been reported as of the financial statement dates.

Claims payable is estimated using various actuarial and statistical methods that use both historical financial and operating data. Management believes that the claims payable liability is adequate to satisfy the ultimate claims liabilities. There is a reasonable possibility that the estimates could change by a material amount in the near term. The estimates for claims payable are continually reviewed and adjusted as necessary as experience develops or new information becomes known. Such adjustments are included in current operations. The claims payable and reserves for incurred but unreported claims were \$1,319,166 and \$995,725 at June 30, 2023 and 2022, respectively.

Note 8: LONG-TERM DEBT

Long-term debt consisted of the following as of June 30:	2023	2022
Note payable with a financial institution, interest rate is based on the one month LIBOR rate plus 2.45%. The interest rate was 7.49% and 3.29% at June 30, 2023 and 2022, respectively. Interest was payable monthly starting August 1, 2017 and principal payments are paid monthly and commenced on March 1, 2020. The note matures on July 7, 2024, at which time a balloon payment of unpaid principle and interest is due. The Company can make draws on this loan up to \$9,195,274. This note is secured by the restricted cash assets and by all other property obtained as a result of the proceeds received.	\$ 7,783,620	\$ 8,139,152
Note payable with a financial institution, interest rate is based on the one month LIBOR rate plus 2.45%. The interest rate was 7.49% and 3.29% at June 30, 2023 and 2022 respectively. Interest is payable monthly starting August 10, 2017 and principal payments are monthly commencing on March 10, 2020. Note matures on July 7, 2024, at which time a balloon payment of unpaid principle and interest is due. This note is secured by all property obtained as a result of the proceeds received.	5,378,364	5,622,790

Note 8: LONG-TERM DEBT (CONTINUED)	2023	2022
Loan agreement with a financial institution. The interest rate for this loan is a fixed rate of 3.55%. Interest is payable monthly which began August 1, 2017 and the principal balance is due in full at maturity of the loan. The loan matures on July 7, 2024. This note is secured by the restricted cash assets and by all other property obtained as a result of the proceeds received.	\$ 6,166,400	\$ 6,166,400
Loan agreement with a financial institution. The interest rate is a fixed rate of 3.55% at June 30, 2023 and 2022. Interest is payable monthly starting August 1, 2017 and principal payments are monthly commencing on September 1, 2024. The loan matures on July 7, 2047. This note is secured by the restricted cash assets and by all other property obtained as a result of the proceeds received.	2,563,600	2,563,600
Loan agreement with a financial institution. Interest rate is a fixed rate of 1.00%. Interest only payments are due quarterly starting March 10, 2022. Commencing on June 10, 2028 principal and interest payments are due monthly until the loan matures. The loan matures on May 25, 2051. The note is collateralized by all property pledged, mortgaged or assigned on a skilled nursing facility owned by the Company.	1,028,525	1,028,525
Loan agreement with a financial institution. Interest rate is a fixed rate of 1.00%. Interest only payments are due quarterly starting March 10, 2022. Commencing on June 10, 2028 principal and interest payments are due monthly until the loan matures. The loan matures on May 25, 2051. The note is collateralized by all property pledged, mortgaged or assigned on a skilled nursing facility owned by the Company.	5,000,000	5,000,000
Loan agreement with a financial institution. Interest rate is a fixed rate of 1.00%. Interest only payments are due quarterly starting March 10, 2022. Commencing on June 10, 2028 principal and interest payments are due monthly until the loan matures. The loan matures on May 25, 2051. The note is collateralized by all property pledged, mortgaged or assigned on a skilled nursing facility owned by the Company.	1,471,475	1,471,475

Note 8: LONG-TERM DEBT (CONTINUED)	2023	2022
Loan agreement with a financial institution. Interest rate is calculated at LIBOR rate plus 3.80% or the LIBOR Successor Rate, as applicable. The interest rate was 8.84% and 4.67% at June 30, 2023 and 2022, respectively. Interest only payments are due monthly. Commencing on June 15, 2023 principal and interest payments are due monthly until the loan matures. The loan matures on May 25, 2026. The note is collateralized by all property pledged, mortgaged or assigned on a skilled nursing facility owned by the Company.	\$ 6,583,071	\$ 6,597,900
Loan agreement with a financial institution. Interest rate is a fixed rate of 1.68%. Interest only payments are due quarterly starting March 5, 2022. Commencing on June 5, 2028 principal and interest payments are due monthly until the loan matures. The loan matures on May 25, 2051. The note is collateralized by all property pledged, mortgaged or assigned on a skilled nursing facility owned by the Company.	2,222,100	2,222,100
Loan agreement with a financial institution. Interest rate is a fixed rate of 1.68%. Interest only payments are due quarterly starting March 5, 2022. Commencing on June 5, 2028 principal and interest payments are due monthly until the loan matures. The loan matures on May 25, 2051. The note is collateralized by all property pledged, mortgaged or assigned on a skilled nursing facility owned by the Company.	6,597,900	6,597,900
Loan agreement with a financial institution. Interest rate is a floating interest rate calculated using the SOFR Rate plus 325 basis points with a floor of 4.25%. The interest rate was 8.10% and 4.75% at June 30, 2023 and 2022, respectively. Interest only payments are payable starting September 10, 2022 with a balloon payment of principal and outstanding interest due at maturity, December 10, 2024. The note is collateralized by a first mortgage of certain skilled nursing facilities owned by the Company.	36,267,000	36,267,000

Note 8: LONG-TERM DEBT (CONTINUED)	2023	2022
Loan agreements with a financial institution. Interest rate is calculated using the Benchmark Rate in U.S. Dollars provided by American Financial Exchange on the first day of each month rounded to the nearest one-eighth of one percent, plus 220 basis points with a floor of 2.20%. The interest rate was 7.45% and 3.20% at June 30, 2023 and 2022, respectively. Interest and principal payments were payable starting June 19, 2022 with a balloon payment of principal and outstanding interest due at maturity, May 19, 2027. The note is collateralized by a first priority lien of certain skilled nursing facilities owned by the Company.	\$ 39,093,227	\$ 40,727,787
Non-revolving line of credit with a financial institution up to \$22,375,552. Interest rate is calculated using the one month LIBOR plus 2.60%. The interest rate was 7.75% and 3.47% at June 30, 2023 and 2022, respectively. Interest only payments were payable starting July 15, 2021 with a balloon payment of principal and outstanding interest due at maturity, July 15, 2026. The note is collateralized by a first priority lien of certain skilled nursing facilities owned by the Company.	22,185,531	16,379,368
A loan with a financial institution, interest rate is calculated using the one month LIBOR or LIBOR Successor Rate plus 2.70%. The interest rate at was 7.85% and 3.57% at June 30, 2023 and 2022, respectively. Interest only payments were payable starting June 1, 2021 with principal and interest payments commencing on June 5, 2023. The note matures May 25, 2028. The Company can make draws on this loan up to \$6,496,200.	6,479,995	1,321,864
A loan with a financial institution, interest rate is a fixed rate at 3.50%. Principal and Interest payments are payable starting July 1, 2023. The note matures July 1, 2052. The note is collateralized by a first priority lien of certain skilled nursing facilities owned by the Company and is insured by HUD under section 232 of the National	28,996,489	-

Housing Act.

Note 8: LONG-TERM DEBT (CONTINUED)	2023	2022
A loan with a financial institution, interest rate is a fixed rate at 2.69%. Principal and Interest payments are payable starting July 1, 2023. The note matures March 1, 2057. The note is collateralized by a first priority lien of certain skilled nursing facilities owned by the Company and is insured by HUD under section 232 of the National Housing Act.	\$ 10,652,280	\$ -
LPFA Revenue Bonds Series 2014. The bond matures on September 4, 2026 with principal payments due annually and interest payments due quarterly. Interest is a fixed rate at 3.75%. The bonds are collateralized by a first mortgage of an assisted and independent living facility owned by the Company which the bonds were used to finance.	33,459,069	-
A loan with a financial institution, interest rate is calculated using the CME Term SOFR 1MO plus 2.55%. The interest rate at June 30, 2023 was 7.72%. Principal and Interest payments are payable starting July 13, 2023. The note matures September 4, 2026. The note is collateralized by a continuing lien and security interest in and a right of set-off and compensation against all property of the Company.	19,149,598	-
Seller note payable with an interest rate of 3.5%. Interest only payments until June 2025, the principal and interest payments are based on a 15 year amortization. The note matures on June 13, 2028.	550,000	-
Total debt obligations	\$ 241,628,244	\$ 140,105,861
Less unamortized deferred financing costs, net	(2,786,336)	(3,021,469)
Less unamortized discount on fair value of assumed debt	(9,750,240)	-
Less current portion of debt	(7,012,805)	(2,304,062)
Long-term debt	\$ 222,078,863	\$ 134,780,330
Maturities of principal in the subsequent fiscal years are as follows:		
2024 2025 2026 2027 2028	\$	7,012,805 61,757,795 12,377,189 99,800,868 6,377,000
Thereafter		54,302,587
<u>Total</u>	\$	241,628,244

Note 8: LONG-TERM DEBT (Continued)

Substantially all of the loan agreements contain financial covenants pertaining to debt service coverage, net worth and liquidity. The Company was in compliance with the debt service coverage and net worth requirements and has received a waiver for the covenant requiring it to maintain unencumbered liquid assets greater than \$16,000,000 at June 30, 2023. Substantially all of the loan agreements also have reporting requirements that the Company is in compliance with or if not in compliance has the right and the ability to cure any reporting violations.

The unamortized discount on fair value of assumed debt represents the difference between the outstanding principal amount of debt assumed in a business combination and the fair value of the debt based on market interest rates for similar debt instruments at the time of the acquisition. The difference between the outstanding principal and the fair value is amortized over the life of the loan based on the difference between the market interest rate at the time of acquisition and the stated interest rate of the loan assumed.

The Company entered into interest rate swap contracts that effectively convert the interest rate on certain notes payable to fixed rates. The swap agreements commence on dates ranging from July 2, 2020 to July 15, 2023 and end on dates ranging from July 7, 2024 to May 25, 2028. The total notional value of the swap agreements as of June 30, 2023 and 2022 was \$48,607,324 and \$26,856,042 respectively. The notional amount under the swap agreements will decrease as principal payments are made on the notes payable so that the notional amount on the swaps equals the principal outstanding on the notes payable.

The carrying amount of the swaps have been adjusted to the fair values at June 30, 2023 and 2022, which because of changes in forecasted levels of SOFR resulted in a reporting an asset of \$3,358,957 and an asset of \$1,186,825 at June 30, 2023 and 2022, respectively. The change in the asset or liability is reported as a component of non-operating revenues (expenses) on the consolidated statements of revenues, expenses, and changes in net assets.

Note 9: CARES ACT PROVIDER RELIEF FUND

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law by the President of the United States. Included in the CARES Act was a healthcare provider relief fund (PRF), administered by the Department of Health and Human Services (HHS), and to be distributed to healthcare providers. The purpose of the PRF is to help providers offset certain costs incurred as a result of COVID-19 including the impact to the provider's revenue if applicable.

Providers were allocated a portion of the PRF based on prior revenue information reported to CMS in their annual Medicare cost reports. During the year ended June 30, 2022 the Company received \$1,594,732 in PRF payments. For the year ended June 30, 2022 the Company determined that, based on guidance provided by HHS, \$1,594,732 of additional costs or lost revenue related to COVID-19 were allocable to PRF payments received and recognized the amounts as contribution revenue in the 2022 consolidated financial statements. There were no funds received for the year ended June 30, 2023.

Note 10: CONCENTRATIONS OF CREDIT RISK

The Company maintains cash with financial institutions in excess of the FDIC limit of \$250,000 by \$23,311,934 and \$26,082,784 at June 30, 2022 and 2023, respectively.

Note 11: COMMITMENTS

There are various claims and litigation against the Company that could materially affect its financial position at the time of the ultimate settlement of such actions. For medical malpractice cases in Louisiana, the Company is self-insured up to the first \$100,000 per claim and is covered for the excess over \$100,000 up to the statutory malpractice damages "cap" of \$500,000 through enrollment in the Louisiana Patients' Compensation Fund (the Fund). Management is of the opinion that the Company's reserve provides adequate coverage for the first \$100,000 of each claim outstanding. Due to the state of nursing home litigation and the unpredictability of jury verdicts, it is the opinion of management that it is reasonably possible that this estimate will change in the near term. However, the Company does not expect any such changes to the estimate to be material to the Company's consolidated financial statements. The Company has recorded a reserve in the accounts payable and accrued expenses of \$2,016,211 and \$2,200,000 at June 30, 2023 and 2022, respectively, for the claims.

The Company has elected to self-insure employee and eligible dependent health claims. The self-insured claims are processed through a third party plan administrator. The Company's self-insured plan has stop-loss insurance coverage for claims in excess of \$100,000 per individual per plan year and \$125,000 in the aggregate for claims in excess of the individual stop-loss. The Company has recorded a current liability in accounts payable and accrued expenses for open claims and claims incurred but not reported of \$1,029,114 and \$918,510 at June 30, 2023 and 2022, respectively.

Note 12: LEASES

The Company has operating and finance leases for office space, land, and equipment. The leases have remaining terms of two to forty three years, some of which may include options to extend the leases, and some of which may include options to terminate the leases. The optional periods are only included in determining the lease term if the Company determines they are reasonably likely to exercise the option.

The weighted average remaining lease term and weighted average discount rate at June 30, 2023 was 13 years and 3 months and 2.98%, respectively. Lease expense for the years ended June 30, 2023 and 2022, was \$1,324,207 and \$843,430, respectively.

Note 12: LEASES (Continued)

Future minimum lease payments under non-cancellable leases as of June 30, 2023 were as follows:

For the years ending June 30,	
2024	\$ 1,145,233
2025	1,087,336
2026	486,707
2027	409,251
2028	367,810
Thereafter	4,219,437
Total future minimum lease payments	7,715,774
Less imputed interest	 (2,281,263)
Present value of lease liabilities	\$ 5,434,511
The total future minimum lease payments at June 30, 2022 is as follows:	
For the years ending June 30,	
2023	\$ 222,319
2024	209,882
2025	139,572
2026	110,263
2027	108,000
Thereafter	4,698,000
Total	\$ 5.488.036

Note 13: DEFINED CONTRIBUTION PLAN

The Company sponsors a defined contribution plan (the Plan) covering all employees that are at least 21 years of age and have completed one year of service. Under provisions of the plan, the Employer must match 100% of each employee's contributions up to the first 1% of the employee's annual compensation and match 50% of each employee's contribution up to an additional 5% of the employee's annual compensation. Employer contribution expenses were \$1,071,794 and \$800,299 for the years ended June 30, 2023 and 2022, respectively.

Note 14: RELATED PARTIES

During the year ended June 30, 2023, entities controlled by certain members of management acquired non-controlling interests in CCC Pharmacy, LLC and Post Acute Holdings, LLC. For the year ended June 30, 2023 contributions from and distributions to the related parties totaled \$4,977,243 and \$475,000, respectively.

Note 15: FUNCTIONAL CLASSIFICATION OF EXPENSES

Costs related to program administration are functionally classified as supporting services expenses. Any costs related to activities that constitute direct conduct or direct supervision of program activities are program expenses. The Company did not have any fundraising expenses for the year ended June 30, 2023 and 2022. The financial statements report certain categories of expenses that are attributable to more than one program or supporting function of the Company. Therefore, these expenses require allocation on a reasonable basis that is consistently applied.

Nursing services, general and administrative, therapy and ancillary services, cost of pharmacy sales, dietary and food, plant operations and maintenance, provider fees, housekeeping and laundry, activities and social services, bad debt expense, advertising costs, and community services costs have been allocated based on actual direct expenditures excluding salary and benefit costs. Salaries and benefits have been allocated based on time and effort.

Lease expenses have been allocated based on use of space. The table below presents expenses by both their nature and function for the years ended June 30, 2023 and 2022:

For the year ended June 30, 2023	Program	Services	Support Services		Total
Salaries and benefits	\$	63,818,758	\$	23,926,219	\$ 87,744,977
Nursing services		9,769,036		75,818	9,844,854
General and administrative		-		21,029,538	21,029,538
Therapy and ancillary services		6,221,677		3,926,735	10,148,412
Cost of pharmacy sales		10,900,367		-	10,900,367
Dietary and food		4,760,857		-	4,760,857
Depreciation and amortization		5,976,228		2,342,332	8,318,560
Plant operations and		-		6,188,852	6,188,852
maintenance					
Provider fees		6,032,005		-	6,032,005
Housekeeping and laundry		840,351		-	840,351
Activities and social services		245,344		-	245,344
Bad Debt Expense		1,265,953		-	1,265,953
Lease expense		-		1,324,207	1,324,207
Advertising costs		-		156,298	156,298
Community services				57,269	57,269
Total operating expenses	\$	109,830,576	\$	59,027,268	\$ 168,857,844

Note 15: FUNCTIONAL CLASSIFICATION OF EXPENSES (CONTINUED)

For the year ended June 30, 2022	Prograr	n Services	Support Services			Total		
Salaries and benefits	\$	47,138,253	\$	25,211,757	\$	72,350,010		
Nursing services		7,138,396		793,155		7,931,551		
General and administrative		-		16,205,864		16,205,864		
Therapy and ancillary services		6,476,961		2,893,366		9,370,327		
Cost of pharmacy sales		9,133,898		-		9,133,898		
Dietary and food		3,945,319		-		3,945,319		
Depreciation and amortization		5,266,468		2,065,711		7,332,179		
Plant operations and maintenance		-		5,392,887		5,392,887		
Provider fees		5,501,424		-		5,501,424		
Housekeeping and laundry		694,519		-		694,519		
Activities and social services		175,997		-		175,997		
Bad Debt Expense		1,667,229		-		1,667,229		
Lease expense		-		843,430		843,430		
Advertising costs		-		156,109		156,109		
Community services				79,036		79,036		
Total operating expenses	\$	87,138,464	\$	53,641,315	\$	140,779,779		

Note 16: DISCONTINUED OPERATIONS

On February 18, 2021 the Company entered into an agreement for the sale of Senescence, LLC (Hospice). The sale was finalized on July 1, 2021 for \$5,440,000. Concurrent with the sale, the Company remitted \$1,211,659 of accrued distributions to the noncontrolling shareholders in Hospice. The assets, liabilities, and results of Hospice have been classified as discontinued operations on the consolidated balance sheet, consolidated statements of revenues, expenses, and changes in net assets, and the consolidated statement of cash flows for all periods presented. The sale resulted in a \$5,733,182 gain which is included in the gain on disposal of assets on the consolidated statements of revenues, expenses, and change in net assets for the year ended June 30, 2022.

Note 17: ACQUISITIONS

On December 1, 2021 the Company acquired the CON for a 124 bed skilled nursing facility in Metairie, Louisiana in the amount of \$4,500,000. The company is leasing the facility to utilize the CON. In conjunction with the purchase, the Company entered into a two year lease with a related party of the seller, to continue to utilize the existing facility. The Company intends to construct a new facility to fully utilize the CON.

Note 17: ACQUISITIONS (Continued)

The Company formed a joint venture, Post Acute Holdings, LLC (PAH) wherein the Company obtained 55% ownership. On November 16, 2022, PAH purchased the home healthcare and hospice services and licenses of Notre Dame Health Systems for \$11,000,000. Notre Dame Health System is affiliated with the Archdiocese of New Orleans and its home healthcare and hospice serves patients throughout Southeast Louisiana and Coastal Mississippi.

On June 13, 2023, the Company acquired three skilled nursing facilities as well as two assisted living facilities and one independent living facility from Notre Dame Health Systems (the "Seller"). Total consideration paid to the Seller was \$21,442,162 which included a \$550,000 seller note payable. The fair value of the net assets acquired is as follows:

Cash and restricted cash	\$	3,039,889
Real estate		65,446,713
Personal property		4,040,000
Other assets		65,770
Intangible assets (CONs)		21,620,000
Debt assumed		(63,357,597)
Total fair value of not assets assuired	,	20 054 775

Total fair value of net assets acquired \$ 30,854,775

As a result of the fair value of the net assets exceeding the consideration paid by the Company, management reassessed the assets acquired and liabilities assumed and determined that the difference primarily related to the discount of the debt assumed at fair value compared to the amount owed on the outstanding obligations (see Note 8). The difference between the fair value of the net assets acquired and consideration transferred to the Seller was recorded as gain on acquisition of \$9,412,611 for the year ended June 30, 2023.

To finance the acquisition, the Company obtained a note payable from a financial institution in the amount of \$19,149,598. The Company also recorded \$556,312 of acquisition related costs for legal, consulting, and related services. These costs are recorded in general and administrative expenses on the consolidated statements of revenues, expenses and changes in net assets for the year ended June 30, 2023.

Note 18: GAIN ON LEGAL SETTLEMENT

During the year ended June 30, 2022, the Company settled litigation related to a construction project from 2021. As a result of the settlement, the Company received \$1,500,000 which is included in miscellaneous income on the consolidated statements of revenues, expenses, and changes in net assets.

CommCare Corporation Notes to Consolidated Financial Statements

Note 19: SUBSEQUENT EVENTS

On August 1, 2023 the Company sold 55% of the equity interests of Dignity Care Corporation. The transaction consisted of selling 50% of the interests to a third party operator and the remaining 5% to a separate third party. The net proceeds received by the company were approximately \$1.2 million.

On December 28, 2024 the Company sold two skilled nursing and independent living facilities in Jonesville, Louisiana and Center Point, Louisiana for \$25,000,000. After selling costs and payoff of notes payable related to the facilities, the Company received \$14,445,589 in proceeds, of which \$1,000,000 was held in escrow pending final adjustment for working capital and contingencies.



SUPPLEMENTARY INFORMATION

Schedule of Compensation, Benefits, and Other Payments to Agency Head

Agency Head Name: Dr. Patricia Prechter, President and CEO

Purpose	Amount	
Salary	\$	-
Benefits-insurance		-
Benefits-retirement		-
Benefits-medicare		-
Benefits-worker's compensation		-
Benefits-unemployment		-
Cell phone and Ipad dues		-
Uniforms		-
Per diem		-
Reimbursements-advertising		-
Travel		-
Fuel usage		-
Conference travel (Including Hotel Stays)		-
Continuing professional education fees		-
Housing		-
Unvouchered expenses		-
Special meals		-
Total	\$	-

^{*} Louisiana Revised Statute 24:513(A)(3) as amended by Act 706 of the 2014 Regular Legislative Session requires that the total compensation, reimbursements, and benefits of an agency head or political subdivision head or chief executive officer related to the position, including but not limited to travel, housing, unvouchered expenses, per diem, and registration fees be reported as a supplemental report within the financial statement of local governmental and quasi-public auditees. In 2015 Act 462 of the 2015 Regular Session of the Louisiana Legislature further amended R.S. 24:513(A)(3) to clarify that nongovernmental entities or not-for-profit entities that receive public funds shall report only the use of public funds for the expenditures itemized in the supplemental report.

CommCare Corporation Consolidating Balance Sheet

			CommCare	CommCare	CommCare	CommCare		CommCare Center	CommCare	Chateau De Notre Dame Facilities	Our Lady of Wisdom Facility	CommCare		CommCare		Post Acute		
June 30, 2023	Comm	Care	Avoyelles	Natchitoches	Tangipahoa	Catahoula	CommCare EBR	Point	Ouachita	Corporation	Corporation	Management	Dignity Care	Louisiana	CCC Pharmacy	Holdings, LLC	Eliminations	Totals
Assets																		
Current assets																		
Cash and cash equivalents	\$ 8	308,399 \$	5,281	438,667	280,598 \$	10,365	9,716	\$ 6,542 \$	7,232	\$ 8,067	\$ 3,184	\$ 1,513,264 \$	2,975,446 \$	437,525	\$ 1,317,391	402,444 \$	- \$	15,724,121
Restricted cash	, ,	-							, .					560.000				560,000
Accounts receivable, net	17.	253,483								204,428	70,460	3,473,857	336,721	7,509	1,198,279	3,219,165	(4,768,482)	20,995,420
Prepaid expenses and other current assets		348,721	5,329	5,329	57,040	5,329	5,329	5,329	5,329	182,396	119,047	110,374	-	5,329	658,439	49,779	-	4,063,099
Intercompany		055,511)	1,387,596	(2,285,085)	(168,089)	4,900,732	(1,988,886)	6,083,808	1,753,566	(144,836)	(140,573)		-	(342,045)			(677)	-
Total current assets	19,	355,092	1,398,206	(1,841,089)	169,549	4,916,426	(1,973,841)	6,095,679	1,766,127	250,055	52,118	5,097,495	3,312,167	668,318	3,174,109	3,671,388	(4,769,159)	41,342,640
Non-current assets																		
Restricted cash		141,616	170,838	415,604		85,175	85,918	137,382	117,753	1,899,952	865,049		3,000,000					6,919,287
Notes receivable		211,787	1,0,030	413,004		03,173	03,310	137,302	117,733	1,033,332	003,043		3,000,000				(9,926,062)	17,285,725
Investments in majority owned subsidiaries		963,829												13,653,850			(35,617,679)	17,203,723
Intangible assets		394,691									-			86,603	-	11,060,539	(33,017,073)	51,541,833
Goodwill		156,944	-	-	-	-	-	-	-		-	-	-	50,005		11,000,559		6,456,944
Fair value of interest rate swaps		572,499		520,295	266,163										-			3,358,957
Miscellaneous	2,	55,762		320,233	200,103									23,173	3,450	2,823		85,208
Operating lease right-of-use assets, net	4	378,171												23,173	3,430	546,612		5,424,783
Property and equipment, net		202,951	9,240,621	21,814,605	15,286,893	466,429	7,239,524	2,658,123	5,668,126	25,344,740	6,349,104	224,384		497,757	285,344	-	(1,347,930)	229,930,671
Total non-current assets	239,	378,250	9,411,459	22,750,504	15,553,056	551,604	7,325,442	2,795,505	5,785,879	27,244,692	7,214,153	224,384	3,000,000	14,261,383	288,794	11,609,974	(46,891,671)	321,003,408
Total assets	\$ 259,	233,342 \$	10,809,665	20,909,415	15,722,605 \$	5,468,030	5 5,351,601	\$ 8,891,184 \$	7,552,006	\$ 27,494,747	\$ 7,266,271	\$ 5,321,879	6,312,167 \$	14,929,701	\$ 3,462,903	\$ 15,281,362 \$	(51,660,830) \$	362,346,048
Liabilities and Net Assets																		
Current liabilities																		
Accounts payable and accrued expenses		310,189 \$	- \$, ,		6,395	6,395	\$ 6,395 \$	6,395	, -,	\$ 6,395	\$ 3,594,031	2,581,187 \$	637,957	\$ 475,880	4,067,923	(4,927,799) \$	18,341,901
Current portion of long-term debt		542,631	-	324,810	260,119	-	-	-	-	588,518	196,727	-	-	-	-	-		7,012,805
Current portion of operating leases		371,862	-	-	-	-	-	-	-	-	-	-	-	-	-	120,798	-	992,660
Total Current Liabilities	18,	324,682		356,722	292,370	6,395	6,395	6,395	6,395	594,913	203,122	3,594,031	2,581,187	637,957	475,880	4,188,721	(4,927,799)	26,347,366
Long-term liabilities																		
Long-term debt, less current portion																		
and less debt issuance costs	126.	225,365	11,372,015	20,918,206	16,224,554	5,611,007	5,668,191	9,119,207	7,797,318	22,047,401	7,021,661		_				(9,926,062)	222,078,863
Operating Lease liabilities, less current portion		016,037			-	-	-	-	-	-		-	-	-	-	425,814	-	4,441,851
																	/ ·	
Total long-term liabilities	130,	241,402	11,372,015	20,918,206	16,224,554	5,611,007	5,668,191	9,119,207	7,797,318	22,047,401	7,021,661	-	-		-	425,814	(9,926,062)	226,520,714
Total liabilities	148,	566,084	11,372,015	21,274,928	16,516,924	5,617,402	5,674,586	9,125,602	7,803,713	22,642,314	7,224,783	3,594,031	2,581,187	637,957	475,880	4,614,535	(14,853,861)	252,868,080
Net assets without donor restrictions																		
CommCare	104	182,981	(562,350)	(365,513)	(794,319)	(149,372)	(322,985)	(234,418)	(251,707)	4,852,433	41,488	1,727,848	3,730,980	8,107,467	2,987,023	10,666,827	(30,622,692)	103,293,691
Noncontrolling interest in subsidiaries		184,277		-	(.54,515)	-	(322,303)	-	-	-,032,433	-	-,. 27,040	-,. 30,300	6,184,277			(6,184,277)	6,184,277
Total Net Assets	110	567,258	(562,350)	(365,513)	(794,319)	(149,372)	(322,985)	(234,418)	(251,707)	4,852,433	41.488	1,727,848	3,730,980	14,291,744	2,987,023	10,666,827	(36,806,969)	109,477,968
TOTAL INST WZZETZ	110,	207,238	(302,350)	(355,513)	(794,319)	(149,372)	(322,985)	(234,418)	(251,/0/)	4,852,433	41,488	1,/2/,848	3,730,980	14,291,744	2,387,023	10,000,827	(20,000,969)	109,477,968
Total liabilities and net assets	\$ 259,	233,342 \$	10,809,665	20,909,415	15,722,605 \$	5,468,030	5,351,601	\$ 8,891,184 \$	7,552,006	\$ 27,494,747	\$ 7,266,271	\$ 5,321,879	6,312,167 \$	14,929,701	\$ 3,462,903	\$ 15,281,362 \$	(51,660,830) \$	362,346,048

CommCare Corporation Consolidating Statement of Revenues, Expenses, and Changes in Net Assets

For the year ended June 30, 2023	CommCare	CommCare Avoyelles	CommCare Natchitoches	CommCare Tangiphoa	CommCare Catahoula	CommCare EBR	CommCare Center Point	CommCare Ouachita	Chateau De Notre Dame Facilities Corporation	Our Lady of Wisdom Facility Corporation	CommCare Management	Dignity Care	CommCare LA	CCC Pharmacy	Post Acute Holdings, LLC	Eliminations	Total
Revenue without donor restrictions, gains, and other sup		,							,			Diginey core		cccinamacy		Limitations	
Patient service revenue, net	\$ 141,120,195 \$	-	\$ -	\$ -	\$ -	\$ - :	\$ - :	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 5,412,229 \$	(312,320) \$	146,220,104
Pharmacy sales		-	-	-		-	-	-	-					16,939,906		(3,701,764)	13,238,142
Premium Income		-	-	-	-	-	-	-	-	-	-	6,609,277			-		6,609,277
Management fee income	764,835	-	-	-		-	-	-	-		11,323,038				21,435	(11,318,971)	790,337
Lease Income	168,819	857,000	417,098	1,500,000	435,000	438,000	691,000	594,000	169,403	66,864	40,656		42,792			(5,246,511)	174,121
Grant Revenue	10,407,387	-	-	-	-	-	-	-	-	-	-	-			-		10,407,387
Other operating revenues	675,199	-	-	-	-	-	-	-	-	-	172,100	-	60,679	-	40,000		947,978
Total revenue without donor restrictions, gains, and																	
other support	153,136,435	857,000	417,098	1,500,000	435,000	438,000	691,000	594,000	169,403	66,864	11,535,794	6,609,277	103,471	16,939,906	5,473,664	(20,579,566)	178,387,346
Operating expenses	C4 02F 240										1 770 050				2 520 204		CC 224 FF2
Nursing services	61,035,318		-		-			-			1,778,950	-			3,520,284		66,334,552
General and Administrative	20,148,315	1,971	26,651	37,335	1,201	1,157	1,200	1,200	123,740	119,477	8,042,889	8,014,237	45,791	2,690,086	1,304,948		40,560,198
Therapy and ancillary services	14,075,147	-	-	-	-	-	-	-	-	-	-	-	-	-	87,349	(4,014,084)	10,148,412
Cost of goods sold- pharmacy		-	-	-	-	-	-	-	-	-	-	-	-	10,900,367	0	-	10,900,367
Dietary and food	8,873,628	-	-	-		-	-	-	-	-	-	-	-		-		8,873,628
Depreciation and amortization	5,546,075	574,033	461,621	664,961	124,089	290,895	240,105	239,874	41,878	11,094	88,349	-	30,008	52,491	-	(46,913)	8,318,560
Plant operations and maintenance	6,929,233	-	-	-	-	-	-	-	-	-	218,819	-	-		23,082		7,171,134
Provider fees	5,999,031	-	-	-	-	-	-	-	-	-	-	-	-	32,974	-	-	6,032,005
Housekeeping and laundry	4,544,110	-	-	-	-	-	-	-	-	-	-	-	-	-	1,075	-	4,545,185
Activities and social services	1,913,042	-	-	-	-	-	-	-	-	-	-	-	-	-	250,857	-	2,163,899
Bad debt expense	1,265,953	-	-	-		-	-	-	-	-	-	-	-		-		1,265,953
Lease expense	6,451,050	-	-	-		-	-	-	-						119,668	(5,246,511)	1,324,207
Advertising costs	897,465	-	-			-	-	-	-	-	-	-	-	2,481	262,529		1,162,475
Community services	57,269	-	-			-	-	-	-	-	-	-	-				57,269
Management fees	10,550,652												172,330		297,584	(11,020,566)	
Total operating expenses	148,286,288	576,004	488,272	702,296	125,290	292,052	241,305	241,074	165,618	130,571	10,129,007	8,014,237	248,129	13,678,399	5,867,376	(20,328,074)	168,857,844
Operating income	4,850,147	280,996	(71,174)	797,704	309,710	145,948	449,695	352,926	3,785	(63,707)	1,406,787	(1,404,960)	(144,658)	3,261,507	(393,712)	(251,492)	9,529,502
Non-operating revenues (expenses)																	
Loss on disposal of assets	(169,129)													1,801			(167,328)
Miscellaneous income (expense)	5,302										(355,673)	101		(27,486)			(377,756)
Equity in earnings of subsidiaries	1,078,978										(333,073)	101	2,873,800	(27,400)		(3,952,778)	(377,730)
	1,070,370	-	_	-	-	_	-	-	_	-	-	_	2,073,000	-	_	(3,332,776)	-
Gain on equity method investment	205 460	200	14,361	410	146	140	237	204						31,690			432,956
Interest income	385,460	299		410	146	149		204 (552,873)	-			٠.	(8,386)	31,090	-		
Interest expense	(3,767,112)	(757,483)	(452,789)	(562,789)	(421,740)	(419,200)	(629,449)	(552,873)	-			1	(8,386)		-		(7,571,820)
Unrealized gain on swaps	1,885,532	-	272,497	14,103	-	-	-	-	-	-	-	-	-	-	-		2,172,132
Gain on acquisition	9,412,611	(252.404)		(5.40.036)	(404 504)	- (****	(600 040)				(055 670)	-		-		(0.050.000)	9,412,611
Total non-operating revenues (expenses)	8,831,642	(757,184)	(165,931)	(548,276)	(421,594)	(419,051)	(629,212)	(552,669)		-	(355,673)	102	2,865,414	6,005	-	(3,952,778)	3,900,795
Change in net assets without donor restrictions	13,681,789 \$	(476,188)	\$ (237,105)	\$ 249,428	\$ (111,884)	\$ (273,103)	\$ (179,517)	(199,743)	\$ 3,785	\$ (63,707)	\$ 1,051,114	\$ (1,404,858)	\$ 2,720,756	\$ 3,267,512	\$ (393,712) \$	(4,204,270) \$	13,430,297
Less change in net assets attributable																	
to noncontrolling interests		-		-	-	-	-	-	-	-	-	-	(1,293,210)		-	-	(1,293,210)
Total changes in net assets without donor restrictions	13,681,789	(476,188)	(237,105)	249,428	(111,884)	(273,103)	(179,517)	(199,743)	3,785	(63,707)	1,051,114	(1,404,858)	1,427,546	3,267,512	(393,712)	(4,204,270)	12,137,087
·			·		·	·				·	-	-					
Net assets																	-
Beginning of year	93,211,610 \$	(86,162)	\$ (11,695)	\$ 53,832	\$ (37,488)	\$ (49,882)	\$ (54,901)	(51,964)	\$ -	\$ -	\$ 1,786,627	\$ 3,233,238	\$ 3,547,841	\$ 2,393,698	\$ - \$	(11,660,942) \$	92,273,812
Contributions by noncontrolling shareholder in subs	4,977,243	- 1											4,977,243		4,977,243	(9,954,486)	4,977,243
Distributions to noncontrolling shareholder in subs	(1,203,384)	-			-		-						(1,203,384)	(2,674,187)	.,,	3,877,571	(1,203,384)
Intercompany equity transfer	(-,,,		(116,713)	(1,097,579)					4,848,648	105,195	(1,109,893)	1,902,600	4,249,288	(=,0,=0,)	6,083,296	(14,864,842)	(=,===,504)
			(220,713)	(2,037,373)					-,0-0,040	103,133	(2,203,033)	1,502,000	7,273,200		0,003,230	(_4,004,042)	
End of year	\$ 110,667,258 \$	(562,350)	\$ (365,513)	\$ (794,319)	\$ (149,372)	\$ (322,985)	\$ (234,418)	\$ (251,707)	\$ 4,852,433	\$ 41,488	\$ 1,727,848	\$ 3,730,980	\$ 14,291,744	\$ 2,987,023	\$ 10,666,827 \$	(36,806,969) \$	109,477,968



Carr, Riggs & Ingram, LLC 111 Veterans Blvd. Suite 350 Metairie, Louisiana 70005

> (504) 837-9116 (504) 837-0123(fax) www.CRIcpa.com

INDEPENDENT AUDITORS' REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

Board of Directors CommCare Corporation Mandeville, Louisiana

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of CommCare Corporation (the Company) (a nonprofit organization), which comprise the consolidated balance sheet as of June 30, 2023, and the related consolidated statements of revenues, expenses and changes in net assets, and cash flows, for the year then ended, and the related notes to financial statements, and have issued our report thereon dated March 12, 2024.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the Company's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we do not express an opinion on the effectiveness of the Company's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the Company's financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that have not been identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Company's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed an instance of noncompliance or other matters that are required to be reported under Government Auditing Standards and which is described in the accompanying schedule of findings and questioned costs as item 2023-002.

Management's Responses to Finding

Carr, Riggs & Ungram, L.L.C.

Management's responses to the findings identified in our audit is described in the accompanying corrective action plan. Management's responses were not subjected to the auditing procedures applied in the audit of the financial statements and, accordingly, we express no opinion on them.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Company's internal control or on compliance. This report is an integral part of an audit performed in accordance with Government Auditing Standards in considering the Company's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Metairie, Louisiana March 12, 2024



Carr, Riggs & Ingram, LLC 111 Veterans Blvd. Suite 350 Metairie, Louisiana 70005

> (504) 837-9116 (504) 837-0123(fax) www.CRIcpa.com

INDEPENDENT AUDITORS' REPORT ON COMPLIANCE FOR EACH MAJOR PROGRAM AND ON INTERNAL CONTROL OVER COMPLIANCE REQUIRED BY THE UNIFORM GUIDANCE

To the Board of Directors of CommCare Corporation Mandeville, Louisiana

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited CommCare Corporation's (the Company) compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Company's major federal programs for the year ended June 30, 2023. The Company's major federal programs are identified in the summary auditors' results section of the accompanying schedule of findings and questioned costs.

In our opinion the Company complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2023.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of *Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance).* Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Company's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to the Company's federal programs.

Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Company's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Company's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with generally accepted auditing standards, Government Auditing Standards, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and
 design and perform audit procedures responsive to those risks. Such procedures include
 examining, on a test basis, evidence regarding the Company's compliance with the
 compliance requirements referred to above and performing such other procedures as we
 considered necessary in the circumstances.
- Obtain an understanding of the Company's internal control over compliance relevant to the
 audit in order to design audit procedures that are appropriate in the circumstances and to
 test and report on internal control over compliance in accordance with the Uniform
 Guidance, but not for the purpose of expressing an opinion on the effectiveness of the
 Company's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control over Compliance

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance and therefore, material weaknesses or significant deficiencies may exist that were not identified. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, as discussed below, we did identify certain deficiencies in internal control over compliance that we consider to be a significant deficiency.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance. We consider the deficiency in internal control over compliance described in the accompanying schedule of findings and questioned costs as item 2023-001 to be a significant deficiency.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

Government Auditing Standards requires the auditor to perform limited procedures on the Company's response to the internal control over compliance findings identified in our compliance audit described in the accompanying schedule of findings and questioned costs. The Company's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Metairie, Louisiana March 12, 2024

Carr, Riggs & Ungram, L.L.C.

CommCare Corporation Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2023

Federal Grantor/ Pass-through Grantor/ Program or Cluster Title	Assistance Listing Number	Pass-through Entity Identifying Number	Federal Expenditures (\$)	Amount Passed through to Subrecipient	Federal Expenditures (\$)
Department of Health and Human Services					
Direct Program:					
COVID-19 Provider Relief Fund and American					
Rescue Plan (APR) Rural Distribution	93.498	n/a	\$ 1,594,731	\$ -	\$ 1,594,731
Total Direct Program			1,594,731	-	1,594,731
Department of Homeland Security Passed Through State of Louisiana Disaster Grants - Public Assistance					
(Presidentially Declared Disasters)	97.036	n/a	153,621	-	153,621
COVID-19 Disaster Grants - Public Assistance					
(Presidentially Declared Disasters)	97.036	n/a	10,255,783	2,017	10,253,766
Total Passed Through State of Louisiana			10,409,404	2,017	10,407,387
Total Expenditures of Federal Awards			\$ 12,004,135	\$ 2,017	\$ 12,002,118

Notes to the Schedule of Expenditures of Federal Awards For the Year Ended June 30, 2023

Note 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation – This schedule includes the activity of CommCare Corporation (the Company) and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of *Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance).

Note 2: INDIRECT COST RATE

The Company has not elected to use the 10% de minimis indirect cost rate allowed under Uniform Guidance.

Note 3: LOAN

The Company did not expend federal awards related to loans or loan guarantees during the year.

Note 4: FEDERALLY FUNDED INSURANCE

The Company has no federally funded insurance.

Note 5: NONCASH ASSISTANCE

The Company did not receive any federal noncash assistance for the fiscal year ended June 30, 2023.

Note 6: RECONCILIATION OF FEDERAL EXPENDITURES TO CONTRIBUTION AND GRANT REVENUE

The reporting period for Provider Relief Fund (PRF) periods four and five were for distributions received from July 1, 2021 through June 30, 2022. The reporting period for PRF differs from the fiscal year end of the Company. Below is a reconciliation of the schedule of expenditures of federal awards to the contribution and grant revenues as presented on the consolidated statements of revenues, expenses, and changes in net assets of the Company.

Note 6: RECONCILIATION OF FEDERAL EXPENDITURES TO CONTRIBUTION AND GRANT REVENUE (CONTINUED)

For the year ended June 30, 2023:

Total federal expenditures	\$ 12,004,135
Pass through to Subrecipients	(2,017)
Provider Relief Fund revenue recognized June 30, 2022	(1,594,731)
Total grant revenues recognized June 30, 2023	\$ 10,407,387

Note 7: FEMA EXPENDITURES

The recognition and timing of FEMA expenditures and the obligation of funding differs from the fiscal year end of the Company. The federal expenditures for the year ended June 30, 2023 includes \$78,437, \$2,071,816, and \$5,830,790 of expenditures reported in June 30, 2020, 2021, 2022, respectively, on the consolidated statements of revenues, expenses and changes in net assets.

CommCare Corporation Schedule of Findings and Questioned Costs For the Year Ended June 30, 2023

Section I – Summary of Auditors' Results

Financial Statements								
Type of auditors' report iss	ued:		Unmodified					
Internal control over financeMaterial weaknessSignificant deficien		y		X no X none noted				
Noncompliance material to statements noted?		ye	es	<u>X_</u> no				
Federal Awards								
Internal control over majorMaterial weaknessSignificant deficien		ye		X_ no none noted				
Type of auditors' report iss federal programs:	ued on compliance for major		Unmo	dified				
Any audit findings disclose reported in accordance w		_X_ y	ves	none noted				
Identification of major fede	eral programs:							
Federal Assistance Listing Number	Federa	l Program o	r Cluste	er				
93.498		on – Rural D	istribu	tion				
97.036	Disaster Grants – Public Assi	stance (Pres	sidentia	illy Dec	lared Disasters)			
Dollar threshold used to di programs.	stinguish between type A and	B programs	was \$7	750,000) for major federa			
Auditee qualified as a low-	risk auditee for federal purpos	ses?	<u>X</u>	yes	no			
Section II – Consolidated F	inancial Statement Findings							
None noted.								

Section III – Federal Award Findings and Questioned Costs

<u>2023-001 – SIGNIFICANT DEFICIENCY – Internal Controls over Allowable Costs</u>

Department of Health and Human Services – Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution – ALN #93.498 – Program Years 2021 and 2022

Criteria: Per 2 CFR 200.303(a) and 2 CFR 200.403(g) non-federal entities are

required to establish and maintain effective internal controls over federal awards and adequately document costs charged to federal

programs.

Condition: For 10 out of the 60 expenses sampled, CommCare did not maintain

the appropriate employee benefits enrollment forms.

Cause: Appropriate policies and procedures were not implemented to

maintain the appropriate employee benefits enrollment forms.

Effect: Unallowable costs could be charged to federal grants and may be

required to be repaid to the federal agency.

Questioned Costs: None

Auditor's

Recommendation: We recommend that CommCare design, implement, and monitor

controls to ensure the appropriate benefits enrollment forms are

maintained.

Management

Response: See corrective action plan on page 49.

2023-002 - Noncompliance - Late Filing Finding

Criteria: Per Louisiana Revised Statute 24:513, CommCare is required to

complete and submit an audit to the Louisiana Legislative Auditor "within six months of the close of the local auditee's or vendor's

fiscal year."

Condition: CommCare did not complete and submit the audit to the Louisiana

Legislative Auditor within the required time period.

CommCare Corporation Schedule of Findings and Questioned Costs For the Year Ended June 30, 2023

Cause: CommCare did not implement appropriate controls and processes to

ensure that the audit was submitted within the required time period.

Effect: Federal awards could be withheld if the required report is not

submitted timely.

Questioned Costs: None

Auditor's

Recommendation: We recommend CommCare implement controls and processes to

ensure all required reports are submitted timely.

Management

Response: See corrective action plan on page 49.

Section IV – Prior Audit Findings

None noted



CommCare Corporation

March 12, 2024

PART III - Findings Related to Federal Awards

2023-001 Significant Deficiency: Internal controls over Allowable Costs

Status: In progress.

Planned Corrective Action: Management will design, implement, and monitor controls for the retention of employee benefit election forms to adequately document costs charged to federal programs.

Anticipated Completion Date: March 31, 2024

Responsible Party: Alec Lundberg, Chief Financial Officer

2023-002 Noncompliance - Late Filing Finding

Status: In progress.

Planned Corrective Action: Management will implement procedures and controls to ensure compliance with future reporting deadlines.

Anticipated Completion Date: March 31, 2024

Responsible Party: Alec Lundberg, Chief Financial Officer

Alec Lundberg, Chief Financial Officer

- 32 - 950 West Causeway Approach • Mandeville, Louisiana 70471-3082 • Telephone: (504) 324-8950 • Facsimile: (985) 624-3477



Carr, Riggs & Ingram, LLC 111 Veterans Boulevard Suite 350 Metairie, LA 70005

504.837.9116 504.837.0123 (fax) CRIcpa.com

INDEPENDENT ACCOUNTANTS' REPORT ON APPLYING AGREED-UPON PROCEDURES

To the Board of Directors of CommCare Corporation 950 W. Causeway Approach Mandeville, Louisiana 70471

We have performed the procedures enumerated below, which were agreed to by CommCare Corporation (the Company) and the Louisiana Legislative Auditor (LLA) on the control and compliance (C/C) areas identified in the LLA's Statewide Agreed-Upon Procedures (SAUPs) for the fiscal period July 1, 2022 through June 30, 2023. The Company's management is responsible for those C/C areas identified in the SAUPs.

The Company has agreed to and acknowledged that the procedures performed are appropriate to meet the intended purpose of the agreed-upon procedures engagement. This report may not be suitable for any other purpose. The procedures performed may not address all the items of interest to a user of this report and may not meet the needs of all users of this report and, as such, users are responsible for determining whether the procedures performed are appropriate for their purposes.

The procedures and associated results are as follows:

1) Written Policies and Procedures

- A. Obtain and inspect the Entity's written policies and procedures and observe whether they address each of the following categories and subcategories if applicable to public funds and the Entity's operations:
 - a) Budgeting, including preparing, adopting, monitoring, and amending the budget.

Results: No exceptions were found as a result of applying the above procedure.

b) *Purchasing*, including (1) how purchases are initiated, (2) how vendors are added to the vendor list, (3) the preparation and approval process of purchase requisitions and purchase orders, (4) controls to ensure compliance with the Public Bid Law, and (5) documentation required to be maintained for all bids and price quotes.

Results: No exceptions were found as a result of applying the above procedure.

c) **Disbursements**, including processing, reviewing, and approving.

d) Receipts/Collections, including receiving, recording, and preparing deposits. Also, policies and procedures should include management's actions to determine the completeness of all collections for each type of revenue or agency fund additions (e.g., periodic confirmation with outside parties, reconciliation to utility billing after cutoff procedures, reconciliation of traffic ticket number sequences, agency fund forfeiture monies confirmation).

Results: No exceptions were found as a result of applying the above procedure.

e) **Payroll/Personnel**, including (1) payroll processing, (2) reviewing and approving time and attendance records, including leave and overtime worked, and (3) approval process for employee rates of pay or approval and maintenance of pay rate schedules.

Results: No exceptions were found as a result of applying the above procedure.

f) **Contracting**, including (1) types of services requiring written contracts, (2) standard terms and conditions, (3) legal review, (4) approval process, and (5) monitoring process.

Results: No exceptions were found as a result of applying the above procedure.

g) **Travel and Expense Reimbursement**, including (1) allowable expenses, (2) dollar thresholds by category of expense, (3) documentation requirements, and (4) required approvers.

Results: No exceptions were found as a result of applying the above procedure.

h) Credit Cards (and debit cards, fuel cards, purchase cards, if applicable), including (1) how cards are to be controlled, (2) allowable business uses, (3) documentation requirements, (4) required approvers of statements, and (5) monitoring card usage (e.g., determining the reasonableness of fuel card purchases).

Results: No exceptions were found as a result of applying the above procedure.

i) Information Technology Disaster Recovery/Business Continuity, including (1) identification of critical data and frequency of data backups, (2) storage of backups in a separate physical location isolated from the network, (3) periodic testing/verification that backups can be restored, (4) use of antivirus software on all systems, (5) timely application of all available system and software patches/updates, and (6) identification of personnel, processes, and tools needed to recover operations after a critical event.

Results: No exceptions were found as a result of applying the procedure.

2) Board or Finance Committee

- A. Obtain and inspect the board/finance committee minutes for the fiscal period, as well as the board's enabling legislation, charter, bylaws, or equivalent document in effect during the fiscal period, and
 - a) Observe that the board/finance committee met with a quorum at least monthly, or on a frequency in accordance with the board's enabling legislation, charter, bylaws, or other equivalent document.

b) Observe that the minutes referenced or included financial activity relating to public funds if those public funds comprised more than 10% of the Entity's collections during the fiscal period.

Results: No exceptions were found as a result of applying the procedure.

c) Observe whether the board/finance committee received written updates of the progress of resolving audit finding(s), according to management's corrective action plan at each meeting until the findings are considered fully resolved.

Results: No exceptions were found as a result of applying the procedure.

3) Bank Reconciliations

A. Obtain a listing of Entity bank accounts for the fiscal period from management and management's representation that the listing is complete. Ask management to identify the Entity's main operating account. Select the Entity's main operating account and randomly select 4 additional accounts (or all accounts if less than 5). Randomly select one month from the fiscal period, obtain and inspect the corresponding bank statement and reconciliation for each selected account, and observe that:

Results: No exceptions were found as a result of applying the procedure.

a) Bank reconciliations include evidence that they were prepared within 2 months of the related statement closing date (e.g., initialed and dated or electronically logged);

Results: No exceptions were found as a result of applying the procedure.

b) Bank reconciliations include written evidence that a member of management or a board member who does not handle cash, post ledgers, or issue checks has reviewed each bank reconciliation (e.g., initialed and dated, electronically logged); and

Results: Exceptions noted; five of the five accounts selected did not have evidence that a member/management/board member who does not handle cash, post ledgers, or issue checks had reviewed each bank reconciliation.

c) Management has documentation reflecting it has researched reconciling items that have been outstanding for more than 12 months from the statement closing date, if applicable.

Results: No exceptions were found as a result of applying the procedure.

4) Collections (excluding electronic funds transfers)

A. Obtain a listing of deposit sites for the fiscal period where deposits for cash/checks/money orders (cash) are prepared and management's representation that the listing is complete. Randomly select 5 deposit sites (or all deposit sites if less than 5).

- B. For each deposit site selected, obtain a listing of collection locations and management's representation that the listing is complete. Randomly select one collection location for each deposit site (e.g., 5 collection locations for 5 deposit sites), obtain and inspect written policies and procedures relating to employee job duties (if no written policies or procedures, then inquire of employees about their job duties) at each collection location, and observe that job duties are properly segregated at each collection location such that
 - a) Employees responsible for cash collections do not share cash drawers/registers;

Results: No exceptions were found as a result of applying the procedure.

b) Each employee responsible for collecting cash is not responsible for preparing/making bank deposits, unless another employee/official is responsible for reconciling collection documentation (e.g., pre-numbered receipts) to the deposit;

Results: No exceptions were found as a result of applying the procedure.

c) Each employee responsible for collecting cash is not responsible for posting collection entries to the general ledger or subsidiary ledgers, unless another employee/official is responsible for reconciling ledger postings to each other and to the deposit; and

Results: No exceptions were found as a result of applying the procedure.

d) The employee(s) responsible for reconciling cash collections to the general ledger and/or subsidiary ledgers, by revenue source and/or agency fund additions, is (are) not also responsible for collecting cash, unless another employee/official verifies the reconciliation.

Results: No exceptions were found as a result of applying the procedure.

C. Obtain from management a copy of the bond or insurance policy for theft covering all employees who have access to cash. Observe that the bond or insurance policy for theft was enforced during the fiscal period.

Results: No exceptions were found as a result of applying the procedure.

- D. Randomly select two deposit dates for each of the 5 bank accounts selected for Bank Reconciliations procedure #3A (select the next deposit date chronologically if no deposits were made on the dates randomly selected and randomly select a deposit if multiple deposits are made on the same day). Alternatively, the practitioner may use a source document other than bank statements when selecting the deposit dates for testing, such as a cash collection log, daily revenue report, receipt book, etc. Obtain supporting documentation for each of the 10 deposits and:
 - a) Observe that receipts are sequentially pre-numbered.

Results: No exceptions were found as a result of applying the procedure.

b) Trace sequentially pre-numbered receipts, system reports, and other related collection documentation to the deposit slip.

c) Trace the deposit slip total to the actual deposit per the bank statement.

Results: No exceptions were found as a result of applying the procedure.

d) Observe that the deposit was made within one business day of receipt at the collection location (within one week if the depository is more than 10 miles from the collection location or the deposit is less than \$100 and the cash is stored securely in a locked safe or drawer).

Results: Exceptions noted; six of the ten deposits selected were not deposited within one business day of receipt at the collection location.

e) Trace the actual deposit per the bank statement to the general ledger.

Results: No exceptions were found as a result of applying the procedure.

5) Non-Payroll Disbursements (excluding card purchases, travel reimbursements, and petty cash purchases)

A. Obtain a listing of locations that process payments for the fiscal period and management's representation that the listing is complete. Randomly select 5 locations (or all locations if less than 5).

Results: No exceptions were found as a result of applying the procedure.

- B. For each location selected under procedure #5A above, obtain a listing of those employees involved with non-payroll purchasing and payment functions. Obtain written policies and procedures relating to employee job duties (if the agency has no written policies and procedures, then inquire of employees about their job duties), and observe that job duties are properly segregated such that
 - a) At least two employees are involved in initiating a purchase request, approving a purchase, and placing an order or making the purchase;

Results: No exceptions were found as a result of applying the procedure.

b) At least two employees are involved in processing and approving payments to vendors;

Results: No exceptions were found as a result of applying the procedure.

 The employee responsible for processing payments is prohibited from adding/modifying vendor files, unless another employee is responsible for periodically reviewing changes to vendor files;

Results: No exceptions were found as a result of applying the procedure.

d) Either the employee/official responsible for signing checks mails the payment or gives the signed checks to an employee to mail who is not responsible for processing payments; and

e) Only employees/officials authorized to sign checks approve the electronic disbursement (release) of funds, whether through automated clearinghouse (ACH), electronic funds transfer (EFT), wire transfer, or some other electronic means.

Results: No exceptions were found as a result of applying the procedure.

- C. For each location selected under procedure #5A above, obtain the Entity's non-payroll disbursement transaction population (excluding cards and travel reimbursements) and obtain management's representation that the population is complete. Randomly select 5 disbursements for each location, obtain supporting documentation for each transaction, and
 - a) Observe that the disbursement, whether by paper or electronic means, matched the related original itemized invoice and supporting documentation indicates that deliverables included on the invoice were received by the Entity, and

Results: No exceptions were found as a result of applying the procedure.

b) Observe whether the disbursement documentation included evidence (e.g., initial/date, electronic logging) of segregation of duties tested under procedure #5B, as applicable.

Results: No exceptions were found as a result of applying the procedure.

D. Using the Entity's main operating account and the month selected in Bank Reconciliations procedure #3A, randomly select 5 non-payroll-related electronic disbursements (or all electronic disbursements if less than 5) and observe that each electronic disbursement was (a) approved by only those persons authorized to disburse funds (e.g., sign checks) per the Entity's policy, and (b) approved by the required number of authorized signers per the Entity's policy. Note: If no electronic payments were made from the main operating account during the month selected the practitioner should select an alternative month and/or account for testing that does include electronic disbursements.

Results: No exceptions were found as a result of applying the procedure.

6) Credit Cards/Debit Cards/Fuel Cards/Purchase Cards (Cards)

A. Obtain from management a listing of all active credit cards, bank debit cards, fuel cards, and purchase cards (cards) for the fiscal period, including the card numbers and the names of the persons who maintained possession of the cards. Obtain management's representation that the listing is complete.

- B. Using the listing prepared by management, randomly select 5 cards (or all cards if less than 5) that were used during the fiscal period. Randomly select one monthly statement or combined statement for each card (for a debit card, randomly select one monthly bank statement), obtain supporting documentation, and
 - a) Observe whether there is evidence that the monthly statement or combined statement and supporting documentation (e.g., original receipts for credit/debit card purchases, exception

reports for excessive fuel card usage) were reviewed and approved, in writing (or electronically approved), by someone other than the authorized card holder (those instances requiring such approval may constrain the legal authority of certain public officials, such as the mayor of a Lawrason Act municipality, should not be reported); and

Results: Exceptions noted; one of the five cards selected was not reviewed and approved, in writing by someone other than the authorized card holder.

b) Observe that finance charges and late fees were not assessed on the selected statements.

Results: No exceptions were found as a result of applying the procedure.

C. Using the monthly statements or combined statements selected under procedure #6B above, excluding fuel cards, randomly select 10 transactions (or all transactions if less than 10) from each statement, and obtain supporting documentation for the transactions (e.g., each card should have 10 transactions subject to inspection). For each transaction, observe that it is supported by (1) an original itemized receipt that identifies precisely what was purchased, (2) written documentation of the business/public purpose, and (3) documentation of the individuals participating in meals (for meal charges only). For missing receipts, the practitioner should describe the nature of the transaction and observe whether management had a compensating control to address missing receipts, such as a "missing receipt statement" that is subject to increased scrutiny.

Results: Exceptions noted; four of the random transactions selected from the April 2023 credit card statement were not supported with a receipt identifying what was purchased, or written documentation of the business purpose, or the individuals participating in the meals. Three of the random transactions selected from the April 2023 credit card statement were not supported with an itemized receipt.

7) Travel and Travel-Related Expense Reimbursements (excluding card transactions)

A. Obtain from management a listing of all travel and travel-related expense reimbursements during the fiscal period and management's representation that the listing or general ledger is complete. Randomly select 5 reimbursements and obtain the related expense reimbursement forms/prepaid expense documentation of each selected reimbursement, as well as the supporting documentation. For each of the 5 reimbursements selected

Results: No exceptions were found as a result of applying the procedure.

a) If reimbursed using a per diem, observe that the approved reimbursement rate is no more than those rates established either by the State of Louisiana or the U.S. General Services Administration (www.gsa.gov);

Results: No exceptions were found as a result of applying the procedure.

b) If reimbursed using actual costs, observe that the reimbursement is supported by an original itemized receipt that identifies precisely what was purchased;

c) Observe that each reimbursement is supported by documentation of the business/public purpose (for meal charges, observe that the documentation includes the names of those individuals participating) and other documentation required by Written Policies and Procedures procedure #1A(vii); and

Results: No exceptions were found as a result of applying the procedure.

d) Observe that each reimbursement was reviewed and approved, in writing, by someone other than the person receiving reimbursement.

Results: Exception noted; one of the five reimbursements was not reviewed and approved, in writing by someone other than the person receiving the reimbursement.

8) Contracts

A. Obtain from management a listing of all agreements/contracts for professional services, materials and supplies, leases, and construction activities that were initiated or renewed during the fiscal period. Alternatively, the practitioner may use an equivalent selection source, such as an active vendor list. Obtain management's representation that the listing is complete. Randomly select 5 contracts (or all contracts if less than 5) from the listing, excluding the practitioner's contract, and

Results: No exceptions were found as a result of applying the procedure.

a) Observe whether the contract was bid in accordance with the Louisiana Public Bid Law (e.g., solicited quotes or bids, advertised), if required by law;

Results: No exceptions were found as a result of applying the procedure.

b) Observe that the contract was approved by the governing body/board, if required by policy or law (e.g., Lawrason Act, Home Rule Charter);

Results: No exceptions were found as a result of applying the procedure.

c) If the contract was amended (e.g., change order), observe that the original contract terms provided for such an amendment and that amendments were made in compliance with the contract terms (e.g., if approval is required for any amendment, the documented approval); and

Results: No exceptions were found as a result of applying the procedure.

d) Randomly select one payment from the fiscal period for each of the 5 contracts, obtain the supporting invoice, agree the invoice to the contract terms, and observe that the invoice and related payment agreed to the terms and conditions of the contract.

9) Payroll and Personnel

A. Obtain a listing of employees and officials employed during the fiscal period and management's representation that the listing is complete. Randomly select 5 employees or officials, obtain related paid salaries and personnel files, and agree paid salaries to authorized salaries/pay rates in the personnel files.

Results: No exceptions were found as a result of applying the procedure.

- B. Randomly select one pay period during the fiscal period. For the 5 employees or officials selected under procedure #9A above, obtain attendance records and leave documentation for the pay period, and
 - a) Observe that all selected employees or officials documented their daily attendance and leave (e.g., vacation, sick, compensatory);

Results: No exceptions were found as a result of applying the procedure.

b) Observe whether supervisors approved the attendance and leave of the selected employees or officials;

Results: No exceptions were found as a result of applying the procedure.

 Observe that any leave accrued or taken during the pay period is reflected in the Entity's cumulative leave records; and

Results: No exceptions were found as a result of applying the procedure.

d) Observe that the rate paid to the employees or officials agrees to the authorized salary/pay rate found within the personnel file.

Results: No exceptions were found as a result of applying the procedure.

C. Obtain a listing of those employees or officials that received termination payments during the fiscal period and management's representation that the list is complete. Randomly select two employees or officials and obtain related documentation of the hours and pay rates used in management's termination payment calculations and the Entity's policy on termination payments. Agree the hours to the employee's or official's cumulate leave records, agree the pay rates to the employee's or official's authorized pay rates in the employee's or official's personnel files, and agree the termination payment to Entity policy.

Results: No exceptions were found as a result of applying the procedure.

D. Obtain management's representation that employer and employee portions of third-party payroll related amounts (e.g., payroll taxes, retirement contributions, health insurance premiums, garnishments, workers' compensation premiums, etc.) have been paid, and any associated forms have been filed, by required deadlines.

10) Fraud Notice

A. Obtain a listing of misappropriations of public funds and assets during the fiscal period and management's representation that the listing is complete. Select all misappropriations on the listing, obtain supporting documentation, and observe that the Entity reported the misappropriation(s) to the legislative auditor and the district attorney of the parish in which the Entity is domiciled as required by R.S. 24:523.

Results: No exceptions were found as a result of applying the procedure.

B. Observe that the Entity has posted, on its premises and website, the notice required by R.S. 24:523.1 concerning the reporting of misappropriation, fraud, waste, or abuse of public funds.

Results: No exceptions were found as a result of applying the procedure.

11) Information Technology Disaster Recovery/Business Continuity

- A. Perform the following procedures, verbally discuss the results with management, and report "We performed the procedure and discussed the results with management."
 - a) Obtain and inspect the Entity's most recent documentation that it has backed up its critical data (if no written documentation, then inquire of personnel responsible for backing up critical data) and observe evidence that such backup (a) occurred within the past week, (b) was not stored on the government's local server or network, and (c) was encrypted.

Results: We performed the procedure and discussed the results with management.

b) Obtain and inspect the Entity's most recent documentation that it has tested/verified that its backups can be restored (if no written documentation, inquire of personnel responsible for testing/verifying backup restoration) and observe evidence that the test/verification was successfully performed within the past 3 months.

Results: We performed the procedure and discussed the results with management.

c) Obtain a listing of the Entity's computers currently in use and their related locations, and management's representation that the listing is complete. Randomly select 5 computers and observe while management demonstrates that the selected computers have current and active antivirus software and that the operating system and accounting system software in use are currently supported by the vendor.

Results: We performed the procedure and discussed the results with management.

B. Randomly select 5 terminated employees (or all terminated employees if less than 5) using the list of terminated employees obtained in procedure #9C. Observe evidence that the selected terminated employees have been removed or disabled from the network.

Results: No exceptions were found as a result of applying the procedure.

We were engaged by the Company to perform this agreed-upon procedures engagement and conducted our engagement in accordance with attestation standards established by the American

Institute of Certified Public Accountants and applicable standards of *Government Auditing Standards*. We were not engaged to and did not conduct an examination or review, the objective of which would be the expression of an opinion or conclusion, respectively, on those C/C areas identified in the SAUPs. Accordingly, we do not express such an opinion or conclusion.

Had we performed additional procedures, other matters might have come to our attention that would have been reported to you.

We are required to be independent of the Company and to meet our ethical responsibilities, in accordance with the relevant ethical requirements related to our agreed-upon procedures engagement.

The purpose of this report is solely to describe the scope of testing performed on those C/C areas identified in the SAUPs, and the result of that testing, and not to provide an opinion on control or compliance. Accordingly, this report is not suitable for any other purpose. Under Louisiana Revised Statute 24:513, this report is distributed by the LLA as a public document.

Metairie, Louisiana March 12, 2024

Carr, Riggs & Ungram, L.L.C.



CommCare Corporation

March 12, 2024

Louisiana Legislative Auditor 1600 North 3rd Street P.O. Box 94397 Baton Rouge, LA 70804-9397

And

Carr, Riggs & Ingram, LLC 111 Veterans Blvd. Suite 350 Metairie, LA 70005

RE: Management's Response to Statewide Agreed-Upon Procedures CommCare Corporation

Dear Sirs:

CommCare Corporation will review policies and procedures in regard to the results for each procedure exception and make appropriate changes that are cost effective and within our budget constraints.

Sincerely,

Alec Lundberg

Chief Financial Officer